Patent Grant
11903798
Embodiments disclosed herein relate to methods and apparatuses for dressing and treating a wound with topical negative pressure (TNP) therapy, namely dressing kits for TNP.
Many different types of wound dressings are known for aiding in the healing process of a human or animal. These different types of wound dressings include many different types of materials and layers, for example, gauze, pads, foam pads or multi-layer wound dressings. Topical negative pressure (“TNP”) therapy, sometimes referred to as vacuum assisted closure, negative pressure wound therapy, or reduced pressure wound therapy, is widely recognized as a beneficial mechanism for improving the healing rate of a wound. Such therapy is applicable to a broad range of wounds such as incisional wounds, open wounds and abdominal wounds or the like.
TNP therapy assists in the closure and healing of wounds by reducing tissue oedema; encouraging blood flow; stimulating the formation of granulation tissue; removing excess exudates and may reduce bacterial load and thus, infection to the wound. Furthermore, TNP therapy permits less outside disturbance of the wound and promotes more rapid healing.
Embodiments disclosed herein relate to methods and apparatuses for dressing and treating a wound with topical negative pressure (TNP) therapy. For example but without limitation, the embodiments disclosed herein relate to treating a wound with reduced pressure provided from a pump kit. Although not required, any embodiments of the pump kit can be integral, wherein the pump is mounted to or otherwise supported by or adjacent to the dressing. Additionally, although not required, any embodiments of the pump kit can be sterile. As another non-limiting example, some embodiments disclosed herein relate to apparatuses, features, and methods for controlling the operation of a TNP system and/or apparatuses, features, and methods for detecting one or more conditions or parameters of the dressing, such as pressure, temperature, or saturation level, and, although not required, controlling the operation of the pump or other components of the dressing kit accordingly. As another non-limiting example, any embodiments disclosed herein can be configured to provide a visual indication one or more conditions or parameters of the dressing, such as pressure, temperature, or saturation level.
Any of the features, components, or details of any of the arrangements or embodiments disclosed in this application, including those disclosed below, are interchangeably combinable with any other features, components, or details of any of the arrangements or embodiments disclosed herein to form new arrangements and embodiments. With that, the following arrangements are disclosed herein, inter alia.
1. A wound dressing kit for reduced pressure wound therapy, comprising:
2. The wound dressing kit of Arrangement 1, comprising a conduit in fluid communication with the pump assembly and the dressing member.
3. The wound dressing kit of any one of the previous arrangements, comprising a conduit in fluid communication with the pump assembly and the dressing member, the conduit being selectively removable from the dressing member.
4. The wound dressing kit of any one of the previous arrangements, comprising a conduit positioned on a third dressing portion of the dressing member, the dressing member having a score along at least a portion of the dressing member between the first and the third dressing portions and/or the second and the third dressing portions, the score being configured to increase the tearability of the dressing member between the first and the third dressing portions and/or the second and the third dressing portions.
5. The wound dressing kit of any one of the previous arrangements, comprising a conduit having perforated edges therealong and being configured to extend about a perimeter of the first portion of the dressing member, the conduit being selectively detachable from the first portion of the dressing member by tearing the conduit along at least one perforated edge thereof.
6. The wound dressing kit of anyone of the previous arrangements, comprising a conduit in fluid communication with the pump assembly and the dressing member, the conduit being coiled about the pump assembly in a helical arrangement.
7. The wound dressing kit of any one of the previous arrangements, comprising a conduit in fluid communication with the pump assembly and the dressing member having a connector on an end portion thereof, the connector being configured to activate the pump assembly when engaged with a second connector supported by the first dressing portion.
8. The wound dressing kit of any one of the previous arrangements, wherein the pump assembly comprises a voice coil actuated pump.
9. The wound dressing kit of any one of the previous arrangements, wherein the score comprises a plurality of perforations, channels, partial thickness cuts, and notches configured to increase the tearability of the dressing along the score.
10. The wound dressing kit of any one of the previous arrangements, wherein the power source is removable from the pump assembly by tearing the dressing along a score in the second dressing portion between the power source and the pump assembly.
11. The wound dressing kit of any one of the previous arrangements, wherein the pump is powered by a single 1200 mAh lithium battery.
12. The wound dressing kit of any one of the previous arrangements, wherein the pump is powered by one or more printed batteries.
13. The wound dressing kit of any one of the previous arrangements, wherein the pump is powered by one or more flexible batteries having a thickness of from approximately 450 microns to approximately 770 microns.
14. The wound dressing kit of any one of the previous arrangements, wherein the pump is powered by one or more flexible batteries having a thickness of from approximately 450 microns to approximately 500 microns.
15. The wound dressing kit of any one of the previous arrangements, wherein the pump is powered by 10 or more interconnected batteries.
16. The wound dressing kit of any one of the previous arrangements, wherein the pump is powered by one or more flexible batteries having a thickness of less than approximately 500 microns.
17. The wound dressing kit of any one of the previous arrangements, wherein the pump assembly is powered by one or more flexible batteries positioned about at least one of the first dressing portion and a conduit configured to communicate a source of negative pressure from the pump assembly to the one or more absorptive layers.
18. The wound dressing kit of any one of the previous arrangements, wherein the pump assembly is powered by one or more flexible batteries supported by the first dressing portion beneath the backing layer.
19. The wound dressing kit of any one of the previous arrangements, wherein the pump assembly is powered by one or more flexible batteries supported by the first dressing portion, the one or more flexible batteries being embedded within the one or more absorptive layers.
20. The wound dressing kit of any one of the previous arrangements, wherein the pump assembly is powered by one or more flexible batteries supported by the first dressing portion outside of the backing layer.
21. The wound dressing kit of any one of the previous arrangements, wherein the pump assembly is powered by one or more air activatable batteries.
22. The wound dressing kit of any one of the previous arrangements, wherein the dressing member has a wound contact layer and a transmission layer positioned between the wound contact layer and the backing layer.
23. The wound dressing kit of any one of the previous arrangements, wherein the pump is at least partially powered by one or more photovoltaic cells.
24. The wound dressing kit of any one of the previous arrangements, wherein the pump is at least partially powered by one or more photovoltaic cells positioned about at least one of the dressing backing layer, a housing for the pump assembly, and a conduit configured to communicate a negative pressure provided by the pump assembly to the one or more absorptive layers.
25. The wound dressing kit of any one of the previous arrangements, wherein the pump is at least partially powered by one or more batteries attachable to the dressing member using snap connectors, adhesive, Velcro, a housing having a closeable opening, or a pouch supported by the dressing member.
26. The wound dressing kit of any one of the previous arrangements, further comprising a flexible hinge positioned between the power source and the pump assembly to improve the flexibility and conformability of the portion of the dressing kit supporting the pump and the power source.
27. The wound dressing kit of any one of the previous arrangements, comprising a V-shaped cut out in the dressing layer between the pump assembly and the power source.
28. The wound dressing kit of any one of the previous arrangements, comprising a OLED display.
29. The wound dressing kit of any one of the previous arrangements, comprising a one or more indicator lights configured to indicate a condition of the dressing kit.
30. The wound dressing kit of any one of the previous arrangements, comprising a pull tab, button, conductive label, or switch configured to activate the power source.
31. The wound dressing kit of any one of the previous arrangements, comprising a first packaging member configured prevent an electrical connection between the power source and the pump assembly while the power source is supported by the first packaging member.
32. The wound dressing kit of any one of the previous arrangements, comprising a pressure indicator supported by the first dressing portion configured to provide a visual indication of a level of pressure beneath the backing layer.
33. The wound dressing kit of any one of the previous arrangements, comprising a saturation indicator supported by the first dressing portion configured to provide a visual indication of a level of liquid saturation beneath the backing layer.
34. The wound dressing kit of any one of the previous arrangements, wherein the first portion of the dressing member has one or more features or colored regions detectable only when the backing layer is drawn against the one or more features or colored regions, the dressing kit being configured such that the backing layer is drawn against the one or more features or colored regions when a threshold level of negative pressure is achieved under the backing layer.
35. The wound dressing kit of any one of the previous arrangements, comprising n activation switch or button configured to move between a first on position and a second off position, the switch or button being configured to remain in the first position when a threshold level of negative pressure is maintained beneath the backing layer.
36. The wound dressing kit of Arrangement 36, wherein the switch or button is configured to move to the second position when the level of negative pressure under the backing layer is less than a threshold level of negative pressure and the pump assembly exceeds a threshold flow rate or has been operating continuously for a threshold period of time.
37. The wound dressing kit of Arrangement 36, wherein the switch or button is configured to move to the second position when the level of negative pressure under the backing layer is less than 60 mmHg and the pump assembly has been operating continuously for 4 minutes.
38. The wound dressing kit of Arrangement 36, wherein the switch or button comprises a depressible dome and a tact switch.
39. A wound dressing kit for reduced pressure wound therapy, comprising:
40. The wound dressing kit of Arrangement 39, wherein:
41. The wound dressing kit of Arrangement 40, wherein the plurality of batteries each have a thickness of from approximately 450 microns to approximately 500 microns.
42. The wound dressing kit of any one of Arrangements 39-41, wherein:
43. The wound dressing kit of any one of Arrangements 39-42, comprising a conduit having perforated edges therealong and being configured to extend about a perimeter of the first portion of the dressing member, the conduit being selectively detachable from the first portion of the dressing member by tearing the conduit along at least one perforated edge thereof.
44. The wound dressing kit of any one of Arrangements 39-42, comprising a conduit in fluid communication with the pump assembly and the dressing member, the conduit being coiled about the pump assembly in a helical arrangement.
45. The wound dressing kit of any one of Arrangements 39-44, wherein the pump assembly comprises a voice coil actuated pump.
46. The wound dressing kit of any one of Arrangements 39-45, comprising a pull tab, button, conductive label, or switch configured to activate the power source.
47. The wound dressing kit of any one of Arrangements 39-46, comprising a pressure indicator supported by the dressing member configured to provide a visual indication of a level of pressure beneath the backing layer.
48. The wound dressing kit of any one of Arrangements 39-46, comprising a saturation indicator supported by the dressing member configured to provide a visual indication of a level of liquid saturation beneath the backing layer.
49. A wound dressing kit for reduced pressure wound therapy, comprising:
50. The wound dressing kit of Arrangement 49, wherein the dressing member comprises one or more absorptive layers and a fluid impermeable backing layer over the one or more absorptive layers, wherein the pump assembly is supported adjacent to one or more of the absorptive layers.
51. The wound dressing kit of any one of Arrangements 49-50, wherein the pump assembly comprises a voice coil actuated pump.
52. The wound dressing kit of any one of Arrangements 49-51, comprising a pull tab, button, conductive label, or switch configured to activate the power source.
53. The wound dressing kit of any one of Arrangements 49-52, comprising a pressure indicator supported by the dressing member configured to provide a visual indication of a level of pressure beneath the backing layer.
54. The wound dressing kit of any one of Arrangements 49-53, comprising a saturation indicator supported by the dressing member configured to provide a visual indication of a level of liquid saturation beneath the backing layer.
55. The wound dressing kit of Arrangements 49-54 or any one of the previous arrangements, comprising a viewing window in an opaque backing layer, the viewing window being configured to permit a user to determine a level of saturation within the dressing member.
56. A wound dressing kit for reduced pressure wound therapy, comprising:
57. The wound dressing kit of Arrangement 56, wherein the pump has a port that is in direct fluid communication with the transmission layer, such that negative pressure is applied by the pump assembly directly to the transmission layer.
58. The wound dressing kit of any one of Arrangements 56-57, further comprising a liquid barrier or liquid filter in communication with the pump assembly and configured to prevent the passage of liquid into the pump.
59. The wound dressing kit of any one of Arrangements 56-58, wherein the opening does not extend into the transmission layer.
60. The wound dressing kit of any one of Arrangements 56-59, wherein the opening extends through the transmission layer.
61. The wound dressing kit of any one of Arrangements 56-60, further comprising an impermeable film between the absorption layer and the transmission layer, the impermeable film having an opening therein in communication with a port in the pump assembly configured to permit the passage of negative pressure from the pump assembly into the transmission layer.
62. The wound dressing kit of any one of Arrangements 56-61, wherein the pump assembly is configured to transfer liquid from the transmission layer through the pump into the absorption layer.
63. The wound dressing kit of any one of Arrangements 56-62, wherein the pump assembly is covered by the backing layer.
64. The wound dressing kit of Arrangements 63, further comprising a vent hole in the backing layer configured to permit exhaust air from the pump assembly to pass through the backing layer.
65. The wound dressing kit of any one of Arrangements 56-64, wherein the pump assembly comprises a voice coil actuated pump.
66. The wound dressing kit of any one of Arrangements 56-64, comprising a pull tab, button, conductive label, or switch configured to activate the power source.
67. The wound dressing kit of any one of Arrangements 56-66, comprising a pressure indicator supported by the dressing member configured to provide a visual indication of a level of pressure beneath the backing layer.
68. The wound dressing kit of any one of Arrangements 56-67, comprising a saturation indicator or sensor supported by the dressing member configured to provide a visual indication of a level of liquid saturation beneath the backing layer.
69. The wound dressing kit of Arrangement 68, wherein the saturation indicator or sensor is positioned adjacent to the pump assembly.
70. The wound dressing kit of any one of Arrangements 56-69, further comprising a power source configured to provide a source of power to at least the pump assembly.
71. The wound dressing kit of any one of Arrangements 56-70, wherein the backing layer is opaque, and comprising one or more viewing windows in the backing layer configured to permit a user to determine a level of saturation within the dressing member.
72. A method of treating a wound, comprising;
Embodiments of the present disclosure will now be described hereinafter, by way of example only, with reference to the accompanying drawings in which:
Embodiments disclosed herein relate to apparatuses and methods of treating a wound with reduced pressure. It will be understood that embodiments of the present disclosure are generally applicable to use in topical negative pressure (“TNP”) therapy systems. Briefly, negative pressure wound therapy assists in the closure and healing of many forms of “hard to heal” wounds by reducing tissue oedema, encouraging blood flow and granular tissue formation, and/or removing excess exudate and can reduce bacterial load (and thus infection risk). In addition, the therapy allows for less disturbance of a wound leading to more rapid healing. TNP therapy systems can also assist in the healing of surgically closed wounds by removing fluid and by helping to stabilize the tissue in the apposed position of closure. A further beneficial use of TNP therapy can be found in grafts and flaps where removal of excess fluid is important and close proximity of the graft to tissue is required in order to ensure tissue viability.
As is used herein, reduced or negative pressure levels, such as −X mmHg, represent pressure levels that are below standard atmospheric pressure, which corresponds to 760 mmHg (or t atm, 29.93 inHg, 101.325 kPa, 14.696 psi, etc.). Accordingly, a negative pressure value of −X mmHg reflects absolute pressure that is X mmHg below 760 mmHg or, in other words, an absolute pressure of (760−X) mmHg. In addition, negative pressure that is “less” or “smaller” than X mmHg corresponds to pressure that is closer to atmospheric pressure (e.g., −40 mmHg is less than −60 mmHg). Negative pressure that is “more” or “greater” than −X mmHg corresponds to pressure that is further from atmospheric pressure (e.g., −80 mmHg is more than −60 mmHg).
Any of the wound dressing embodiments disclosed herein can be located over a wound site to be treated. The dressing can form a substantially sealed cavity or enclosure over the wound site. It will be appreciated that throughout this specification reference is made to a wound. In this sense it is to be understood that the term wound is to be broadly construed and encompasses open and closed wounds in which skin is torn, cut or punctured or where trauma causes a contusion, or any other surficial or other conditions or imperfections on the skin of a patient or otherwise that benefit from reduced pressure treatment. A wound is thus broadly defined as any damaged region of tissue where fluid may or may not be produced. Examples of such wounds include, but are not limited to, acute wounds, chronic wounds, surgical incisions and other incisions, subacute and dehisced wounds, traumatic wounds, flaps and skin grafts, lacerations, abrasions, contusions, burns, diabetic ulcers, pressure ulcers, stoma, surgical wounds, trauma and venous ulcers or the like. In some embodiments, the components of the TNP system described herein can be particularly suited for incisional wounds that exude a small amount of wound exudate.
In any of the apparatus embodiments disclosed herein, as in the embodiment illustrated in
Any of the wound dressing embodiments disclosed herein can be arranged or configured to operate without the use of an exudate canister. Any dressing embodiments can be configured to have a film having a high water vapour permeability to enable the evaporation of surplus fluid, and can have a superabsorbing material contained therein to safely absorb wound exudate. Some embodiments of the apparatus are designed for single-use therapy and can be disposed of in an environmentally friendly manner after an approximately maximum usage of from seven to eleven days. Some embodiments of the pump are designed for an operation period of up to fourteen days, and some for up to twenty days. The pump can be programmed to automatically terminate therapy after a desired number of days, e.g., after seven days, further operation of the pump will not be possible. Some embodiments are designed for longer or repeated usage, and can be configured to support an exudate canister.
In any dressing kit embodiments, including without limitation the illustrated embodiments, the pump assembly can be of a sufficiently small and portable size to be supported on or adjacent to the dressing, or on another location of a user's body or in a user's clothing. For example and without limitation, as will be described in greater detail below, in any of the embodiments disclosed herein, the pump assembly can be attached to a specially formed depression or space on the dressing, can be embedded within, supported on top of or adjacent to one or more absorbent or other dressing layers, or can be otherwise supported by the dressing. Additionally, in any embodiments disclosed or incorporated by reference herein (collectively referred to as “disclosed herein”), the pump assembly can be sized to be attached using adhesive medical tape or otherwise to a person's skin in a comfortable location, adjacent to or on the dressing or otherwise, or can be sized to fit within a person's pants or shirt pocket or tethered to a person's body using a lanyard, pouch, or other suitable device or article.
Any of the dressing kit embodiments disclosed herein can be manufactured in a wide variety of different models or versions, wherein the size of the dressing can be varied to accommodate a wide range of wound sizes. For example, any of the dressing kits can be made having the following sizes of dressings and wound pads or other absorbent elements. In any embodiments disclosed herein, the size of the dressing or the wound pad can be defined by the area of the dressing or the wound pad, wherein the specific length and width (if rectangular) can be varied to accommodate a wider range of wound sizes. For example, the dressings and/or wound pads can be rectangular, circular, ovular, triangular, pentagonal, hexagonal, trapezoidal, or otherwise. The shape and dimensions of the various dressings and wound pads can fall within any of the area ranges listed below, otherwise disclosed in this application, or otherwise. Thus, the dressing dimensions and shapes are not limited to those specified in this disclosure but can be any suitable size and shape.
In any embodiments disclosed herein, the dressing can be sized such that the pad or absorptive portion of the dressing is approximately 50×100 mm, 100×150 mm, 100×250 mm, or any size within these ranges. Some embodiments of the dressing can be configured to be universal, so that one dressing size, shape, and configuration can be adhered to the hips, arms, thighs, torso, back, and/or other body parts.
Some embodiments of the overlay or dressing can be substantially impervious to air flow and the flow of bacteria or other contaminants through the overlay layer, while being pervious to vapor transmission.
As described in greater detail in U.S. patent application Ser. No. 13/092,042, which is hereby incorporated by reference in its entirety as if fully set forth herein, in any of the dressing embodiments disclosed herein, a layer of absorbent material can be provided above the transmission layer. The absorbent material which can be a foam or non-woven natural or synthetic material and can optionally include or be super-absorbent material that can form a reservoir for fluid, particularly liquid, removed from the wound site and draws those fluids towards a cover layer. The material of the absorbent layer can prevent liquid collected in the wound dressing from flowing in a sloshing manner. The absorbent layer can also help distribute fluid throughout the layer via a wicking action so that fluid is drawn from the wound site and stored throughout the absorbent layer. This helps prevent agglomeration in areas of the absorbent layer. The capacity of the absorbent material must be sufficient to manage the exudates flow rate of a wound when negative pressure is applied. Since in use the absorbent layer experiences negative pressure, the material of the absorbent layer can be selected to absorb liquid. A number of materials exist that are able to absorb liquid when under negative pressure, for example superabsorber material. For example and without limitation, any embodiments of the absorbent layer can be manufactured using ALLEVYN™ foam, Freudenberg 114-224-4 and/or Chem-Posite™ 11C-450, or any other suitable material. Other materials may be more appropriate for and can be used in and of the dressing embodiments disclosed herein. Suitable superabsorbers can have polyacrylate or carbomethoxycellulose based materials in the form of granules or fibers or combinations thereof.
In any embodiments disclosed herein, the absorbent layer can be a layer of non-woven cellulose fibers having super-absorbent material in the form of dry particles dispersed throughout. In some arrangements, the use of natural and/or synthetic fibres such as cotton, cellulose and viscose fibres can introduce fast wicking elements which help quickly and evenly distribute liquid taken up by the dressing. The juxtaposition of multiple strand-like fibers leads to strong capillary action in the fibrous pad which helps distribute liquid. In this way, the super-absorbent material is efficiently supplied with liquid. Also, all regions of the absorbent layer are provided with liquid.
The wicking action can also assist in bringing liquid into contact with the upper cover layer to aid increase transpiration rates of the dressing. The wicking action can also assist in delivering liquid downward towards the wound bed when exudation slows or halts. This delivery process helps maintain the transmission layer and lower wound bed region in a moist state which helps prevent crusting within the dressing. Crusting could lead to blockage both within the dressing layers or components beneath the cover or backing layer, and also within the port and/or conduit which can inhibit the flow of wound fluids in the dressing and also inhibit a flow of reduced pressure to the wound or portions of the wound. Thus, the delivery process can help maintain an environment optimized for wound healing.
A layer of porous material can be located above the wound contact layer. This porous layer, or transmission layer, allows transmission of fluid including liquid and gas away from a wound site into upper layers of the wound dressing. In particular, the transmission layer can ensure that an open air channel can be maintained to communicate negative pressure over the wound area even when the absorbent layer has absorbed substantial amounts of exudates. The layer should remain open under the typical pressures that will be applied during negative pressure wound therapy as described above, so that the whole wound site sees an equalized negative pressure. The layer can be formed of a material having a three dimensional structure. For example, a knitted or woven spacer fabric (for example Baltex 7970 weft knitted polyester) or a non-woven fabric can be used. Other materials can be utilized, and examples of such materials are described in U.S. patent application Ser. No. 13/092,042, which are hereby incorporated by reference and made part of this disclosure.
In any embodiments disclosed herein, the transmission layer can have a 3D polyester spacer fabric layer, such as with any embodiments of the dressing disclosed in U.S. Patent Application Publication No. 2011/0282309 (Ser. No. 13/092,042), (titled WOUND DRESSING AND METHOD OF USE), filed Apr. 21, 2011, which application is hereby incorporated by reference as if fully set forth herein. Some embodiments of the transmission layer can have a top layer (that is to say, a layer distal from the wound-bed in use) which is a 84/144 textured polyester (which can be approximately 24.5%, or from approximately 22% to approximately 27% in terms of material composition), and a bottom layer (i.e., a layer which lies proximate to the wound bed in use) which can be a 100 denier flat polyester (which can be approximately 31.4%, or from approximately 28% to approximately 34% in terms of material composition), and a third layer formed sandwiched between these two layers which is a region defined by a knitted polyester viscose, cellulose or the like monofilament fiber (which can be approximately 44.1%, or from approximately 40% to approximately 48% in terms of material composition). Other suitable materials and other linear mass densities of fiber can be used.
Additionally, any embodiments of the transmission layer can be formed using any of the following needle arrangement parameters.
This differential between filament counts in the spaced apart layers helps control moisture flow across the transmission layer. Particularly, by having a filament count greater in the top layer, that is to say, the top layer is made from a yarn having more filaments than the yarn used in the bottom layer, liquid tends to be wicked along the top layer more than the bottom layer. In use, this differential tends to draw liquid away from the wound bed and into a central region of the dressing where the absorbent layer helps lock the liquid away or itself wicks the liquid onwards towards the cover layer where it can be transpired.
Material Layer Composition
Preferably, to improve the liquid flow across the transmission layer (that is to say perpendicular to the channel region formed between the top and bottom spacer layers, the 3D fabric is treated with a dry cleaning agent (such as, but not limited to, Perchloro Ethylene) to help remove any manufacturing products such as mineral oils, fats and/or waxes used previously which might interfere with the hydrophilic capabilities of the transmission layer. In some embodiments, an additional manufacturing step can subsequently be carried in which the 3D spacer fabric is washed in a hydrophilic agent (such as, but not limited to, Feran Ice 30 g/l available from the Rudolph Group). This process step helps ensure that the surface tension on the materials is so low that liquid such as water can enter the fabric as soon as it contacts the 3D knit fabric. This also aids in controlling the flow of the liquid insult component of any exudates.
In some embodiments, the absorbent layer can be an air-laid material. Heat fusible fibers can optionally be used to assist in holding the structure of the pad together. It will be appreciated that rather than using super-absorbing particles or in addition to such use, super-absorbing fibers can be utilized according to some embodiments of the present invention. An example of a suitable material is the Product Chem-Posite™ 11 C available from Emerging Technologies Inc (ETi) in the USA.
Optionally, the absorbent layer can include synthetic stable fibers and/or bi-component stable fibers and/or natural stable fibers and/or super-absorbent fibers. Fibers in the absorbent layer can be secured together by latex bonding or thermal bonding or hydrogen bonding or a combination of any bonding technique or other securing mechanism. In any embodiments disclosed herein, the absorbent layer can be formed by fibers which operate to lock super-absorbent particles within the absorbent layer. This helps ensure that super-absorbent particles do not move external to the absorbent layer and towards an underlying wound bed. This is particularly helpful because when negative pressure is applied there is a tendency for the absorbent pad to collapse downwards and this action would push super-absorbent particle matter into a direction towards the wound bed if they were not locked away by the fibrous structure of the absorbent layer.
The absorbent layer can comprise a layer of multiple fibers. Preferably, the fibers are strand-like and made from cellulose, polyester, viscose or the like. Preferably, dry absorbent particles are distributed throughout the absorbent layer ready for use. In any embodiments disclosed herein, the absorbent layer can have a pad of cellulose fibers and a plurality of super absorbent particles. In additional embodiments, the absorbent layer is a non-woven layer of randomly orientated cellulose fibers.
Super-absorber particles/fibers can be, for example, sodium polyacrylate or carbomethoxycellulose materials or the like or any material capable of absorbing many times its own weight in liquid. In some embodiments, the material can absorb more than five times its own weight of 0.9% W/W saline, etc., or more than 15 times its own weight of 0.9% W/W saline, etc., or, in some embodiments, more than 20 times its own weight of 0.9% W/W saline, etc. Preferably, the material is capable of absorbing more than 30 times its own weight of 0.9% W/W saline, etc. The absorbent layer can have one or more through holes located so as to underlie a suction port. In any embodiments disclosed herein, a hydrophobic filter or other filter or object configured to permit the flow of air or gas through the port or openings in the dressing and prevent the flow of liquid or solids through the port or openings in the dressing can be positioned upstream of the pump to prevent any liquids or solids from entering the pump.
In some embodiments, the wound site can be filled partially or completely with a wound packing material. Deeper wounds can benefit from such packing material. The wound packing material can be used in addition to the wound dressing, or can be integral to the wound dressing. The wound packing material generally can comprise a porous and conformable material, for example foam (including reticulated foams), and gauze. Preferably, the wound packing material is sized or shaped to fit within the wound site so as to fill any empty spaces. The wound dressing can then be placed over the wound site and wound packing material overlying the wound site. When a wound packing material is used, once the wound dressing is sealed over the wound site, TNP is transmitted from a pump through the wound dressing, through the wound packing material, and to the wound site. This negative pressure draws wound exudate and other fluids or secretions away from the wound site.
The dressing of any dressing kit embodiments disclosed herein can have a gas impermeable, but moisture vapor permeable, cover layer extending across the width of the wound dressing. The cover layer, which can for example be a polyurethane film (for example, Elastollan SP9109) or any other suitable material having a pressure sensitive adhesive on one side, is substantially gas impermeable, thereby creating a substantially sealed enclosure over the wound. In this way an effective chamber is made between the cover layer and a wound site where a negative pressure can be established. The cover layer can be sealed to the wound contact layer in a border region around the circumference of the dressing, ensuring that no air is drawn in through the border area, for example via adhesive or welding techniques. The cover layer can protect the wound from external bacterial contamination (bacterial barrier) and allows liquid from wound exudates to be transferred through the layer and evaporated from the film outer surface. The cover layer can have a polyurethane film and an adhesive pattern spread onto the film. The polyurethane film is moisture vapor permeable and can be manufactured from a material that has an increased water transmission rate when wet.
An orifice can be provided in the cover film to allow a negative pressure to be applied to the dressing. As mentioned, in some embodiments, a suction port can be sealed to the top of the cover film over the orifice, which can communicate negative pressure through the orifice, or the pump assembly can be mounted directly over the orifice. The port or pump assembly can be adhered and sealed to the cover film using an adhesive such as an acrylic, cyanoacrylate, epoxy, UV curable or hot melt adhesive. If used, the port can be formed from a soft polymer, for example a polyethylene, a polyvinyl chloride, a silicone or polyurethane having a hardness of 30 to 90 on the Shore A scale.
The dressing can have a filter element that is impermeable to liquids, but permeable to gases. The filter element can act as a liquid barrier, to substantially prevent or inhibit liquids from escaping from the wound dressing, as well as an odor barrier. The filter element can also function as a bacterial barrier. In some embodiments, the pore size of the filter element can be approximately 0.2 μm. Suitable materials for the filter material of the filter element include 0.2 micron Gore™ expanded PTFE from the MMT range, PALL Versapore™ 200R, and Donaldson™ TX6628. The filter element thus enables gas to be exhausted through the orifice. Liquid, particulates and pathogens however are contained in the dressing. Other details regarding the filter are disclosed in U.S. patent application Ser. No. 13/092,042 (2011/0282309) and incorporated by reference herein.
The wound dressing and its methods of manufacture and use as described herein may also incorporate features, configurations and materials described in the following patents and patent applications, each of which is incorporated by reference in their entireties herein as if made part of this disclosure: U.S. Pat. Nos. 7,524,315, 7,708,724, 7,909,805; 7,964,766; 8,062,272; 8,080,702, 8,105,295, 8,282,611, and 8,303,552; U.S. Patent Application Publication Nos. 2009/0254054, 2010/0160880, 2010/0274207, 2011/0009838, 2011/0028918, 2011/0054421, 2011/0054423, and 2011/0118683, as well as U.S. App. Ser. No. 29/389,782, filed Apr. 15, 2011, and Ser. No. 29/389,783, filed Apr. 15, 2011. From these incorporated by reference patents and patent applications, features, configurations, materials and methods of manufacture or use for similar components to those described in the present disclosure can be substituted, added or implemented into embodiments of the present application.
In operation, the wound dressing can be sealed over a wound site forming a wound cavity. The pump assembly can provide a source of a negative pressure to the dressing. Fluid can be drawn toward the orifice through the wound dressing from a wound site below the wound contact layer. The fluid can move towards the orifice through the transmission layer. As the fluid is drawn through the transmission layer, wound exudate can be absorbed into the absorbent layer.
The general shape of the wound dressing can be square, ovular, rectangular, or otherwise. The dressing can have rounded corner regions. It will be appreciated that wound dressings according to other embodiments of the present invention can be shaped differently such as square, circular or elliptical dressings, or the like.
The desired size of the wound dressing can be selected based on the size and type of wound it will be used in. In any embodiments, though not required, the wound dressing can measure between 20 and 40 cm on its long axis, and between 10 to 25 cm on its short axis. For example, dressings can be provided in sizes of approximately 10×20 cm, 10×30 cm, 10×40 cm, 15×20 cm, and 15×30 cm, or any other sizes within these ranges or otherwise.
Whilst some embodiments of the present invention have so far been described in which the transmission layer is formed as a 3D knit layer, e.g., two layers spaced apart by a monofilament layer, it will be appreciated that some embodiments of the present invention are not restricted to the use of such a material. In some embodiments, as an alternative to such a 3D knit material, one or more layers of a wide variety of materials could be utilized. In each case, according to embodiments of the present invention, the openings presented by layers of the transmission layer are wider and wider as one moves away from the side of the dressing which, in use will be located proximate to the wound. In any embodiments disclosed herein, the transmission layer can be provided by multiple layers of open celled foam. Though note required, the foam can be reticulated open cell foam. The foam can be hydrophilic or able to wick aqueous based fluids. The pore size in each layer is selected so that in the foam layer most proximate to the wound side in use the pores have a smallest size. If only one further foam layer is utilized that includes pore sizes which are greater than the pore sizes of the first layer. This helps avoid solid particulate being trapped in the lower layer which thus helps maintain the lower layer in an open configuration in which it is thus able to transmit air throughout the dressing. In any embodiments disclosed herein, two, three, four or more foam layers can be included. The foam layers can be integrally formed, for example, by selecting a foam having a large pore size and then repeatedly dipping this to a lesser and lesser extent into material which will clog the pores or alternatively, the transmission layer formed by the multiple foam layers can be provided by laminating different types of foam in a layered arrangement or by securing such layers of foam in place in a known manner.
Some embodiments of the dressing can be configured to permit the repositionability of the dressing. In any embodiments disclosed herein, the dressing can have a wound contact surface that is covered with an adhesive, such as a silicone based adhesive. As described in U.S. patent application Ser. No. 13/092,042, which disclosure is hereby incorporated by reference as if fully set forth herein, though not required, a lower surface of any of the wound dressing embodiments disclosed herein can have an optional wound contact layer. Any of the dressing embodiments disclosed herein can be made without the wound contact layer. The wound contact layer can be a polyurethane layer or polyethylene layer or other flexible layer which can be made porous or perforated, for example via a hot pin process, laser ablation process, ultrasound process or in some other way or otherwise made permeable to liquid and gas. The perforations can enable fluid and/or gas to flow through the layer. The wound contact layer can help prevent tissue ingrowth into the other material of the wound dressing.
The perforations of the contact layer can be sized small enough to meet this requirement but still allow fluid through. For example, the contact layer can have perforations formed as slits or holes having a size ranging from approximately 0.025 mm to approximately 1.8 mm, or from approximately 1.2 mm to approximately 1.8 mm, which are considered small enough to help prevent tissue ingrowth into the wound dressing while allowing wound exudate to flow into the dressing. In any embodiments, therefore, the perforations can be formed as holes ranging in diameter from approximately 1.2 mm to approximately 2.8 mm, or from approximately 1.2 mm to approximately 1.8 mm. The hole spacing or density in any embodiments can be approximately 8 holes/cm2, or from approximately 6 holes/cm2 to approximately 10 holes/cm2. As used throughout this disclosure, unless otherwise defined, the term approximately can be used to describe a range of +/−10% of the stated value. Additionally, in any embodiments of the contact layer, the holes can be formed at approximately a 3.655 mm triangular pitch. Any of the wound contact layer embodiments disclosed herein can be formed from silicone.
The wound contact layer can help hold the whole wound dressing together and help to create an air tight seal around the absorbent pad in order to maintain negative pressure at the wound. The wound contact layer also acts as a carrier for an optional lower and upper adhesive layer (not shown). For example, a lower pressure sensitive adhesive can be provided on the underside surface of the wound dressing whilst an upper pressure sensitive adhesive layer can be provided on the upper surface of the wound contact layer. The pressure sensitive adhesive, which can be a silicone, hot melt, hydrocolloid or acrylic based adhesive or other such adhesives, can be formed on both sides or optionally on a selected one or none of the sides of the wound contact layer. When a lower pressure sensitive adhesive layer is utilized, this helps adhere the wound dressing to the skin around a wound site.
As mentioned, any dressing embodiments for use in the dressing kits disclosed or incorporated by reference herein can have an adhesive covered bottom (e.g., wound contacting) surface. In any embodiments disclosed herein, as mentioned, the adhesive can be a silicone adhesive including, for example, polysiloxanes or polyorganosiloxanes or other polymeric pressure sensitive silicone adhesives. For example, polydimethylsiloxane or the like can be used. The adhesive formulation can be a mixture of alkyl pendant siloxanes, which can be spread and cast as a two part mix with a catalyst such that a final polymerisation step takes place following casting or spreading. In any embodiments disclosed herein, a dressing layer can have a non-perforated silicone adhesive coating (coat weight 130 gsm nominal) and full spread acrylic adhesive (27 to 37 gsm) coated onto opposite sides of an extruded EU30 polyurethane clear film (27 to 37 gsm). Moisture vapour permeability of such an arrangement can be between approximately 367 gm−2/24 hrs to approximately 405 gm−2/24 hrs, or a mean moisture vapour permeability of 382 gm−2/24 hrs.
Some embodiments or arrangements of a silicone adhesive layer suitable for dressing embodiments disclosed herein can have a moisture vapour transmission rate between approximately 350 gm−2/24 hrs and approximately 410 gm−2/24 hrs. Aptly, the average moisture vapour permeability of some embodiments or arrangements of a silicone adhesive layer suitable for dressing embodiments disclosed herein can be approximately 380 gm−2/24 hrs. Some of the dressing embodiments disclosed herein can have a Wacker silres PSA 45 pressure sensitive adhesive coated thereon.
Additionally, any of the dressing embodiments disclosed herein can have an anti-microbial agent or substance incorporated into the dressing or coated on one or more surfaces of the dressing. For example, without limitation, the dressing can contain anti-microbial e.g. nanocrystalline silver agents on the wound contact layer, or otherwise, and/or silver sulphur diazine in the absorbent layer, or otherwise. These respectively can eliminate micro-organisms in the wound and micro-organisms in the absorption matrix. A wound contact layer of any dressing embodiments disclosed herein can have nanocrystalline silver agents, silver salts, copper salts, or gold salts such as, without limitation, those disclosed in U.S. patent application Ser. No. 11/922,894 (titled ANTIMICROBIAL BIGUANIDE METAL COMPLEXES), filed May 21, 2008, which application is incorporated by reference herein as if made part of this disclosure, PHMB, chlorohexadine, peroxide, hypochloride, or other bleaches therein or thereon.
One or more of such agents can be used separately or together. These can reduce or eliminate micro-organisms in the wound and micro-organisms in the absorption matrix. As a still further option other active components, for example, pain suppressants, such as ibuprofen, can be included. Also agents which enhance cell activity, such as growth factors or that inhibit enzymes, such as matrix metalloproteinase inhibitors, such as tissue inhibitors of metalloproteinase (TIMPS) or zinc chelators could be utilized. As a still further option odor trapping elements such as activated carbon, cyclodextrine, zeolite or the like can be included in the absorbent layer or as a still further layer above the filter layer.
Additionally, adhesive fixation strips can be positioned around the peripheral edges of the any of the dressing embodiments disclosed herein to provide additional support to the dressing. Such fixation strips can be advantageous in some situations so as to provide additional sealing against the skin of the patient surrounding the wound site. For example, the sealing or fixation strips can provide additional sealing for when a patient is more mobile. In some cases, the fixation strips can be used prior to activation of the pump assembly, particularly if the dressing is placed over a difficult to reach or contoured area. In any embodiments disclosed herein, the dressing kit can be provided with up to five sealing strips.
Moreover, some embodiments disclosed herein are directed to systems that include negative pressure therapy apparatuses and dressings, and methods and algorithms for operating such negative pressure therapy apparatuses for use with negative pressure therapy dressings. In some embodiments, a negative pressure therapy apparatus comprises a pump assembly configured to, inter alia, provide negative pressure to a wound. Some embodiments of pump assemblies disclosed herein comprise novel and inventive control logic configured to control the operation of the pump assembly. For example, some embodiments comprise novel and inventive control logic configured to control the operation of a pump assembly in response to monitoring and detecting various operating conditions, such as presence and/or severity of a leak or leaks in the system, rate of flow of fluid (e.g., air, liquid and/or solid exudate, etc.) aspirated from a wound, and the like. In some embodiments, the control logic can be configured to detect a leak or leaks in a system (e.g., leak or leaks in the dressing that is in fluid communication with the pump, leak or leaks in the seal created by the dressing over the wound, etc.) as well as to control the operation of the pump assembly when such leak or leaks are detected. In some embodiments, the pump assembly can be configured to distinguish between at least a normal or low leak (e.g., a leak that has a relatively low flow rate), a high leak (e.g., a leak that has a relatively high flow rate), and a very high leak (e.g., a leak that has a relatively very high flow rate). Some embodiments can further be configured to also distinguish between the aforementioned leaks and an extremely high leak.
The operation of the pump can be controlled by the use of one or more buttons, pull tabs, sliding switches, or other similar features.
In some embodiments, the dressing kit can comprise a source of negative pressure, such as a miniature, disposable pump, powered by a power source. The pump assembly can be configured to provide therapy for a predetermined period of time, such as approximately 1 day, 1 or 2 to 10 days, 1 or 2 to 14 days, etc. In some embodiments, the pump assembly can be required to provide uninterrupted therapy for such period of time. In some embodiments, the pump assembly can be configured to deactivate itself a predetermined period of time (e.g., 7 days) after an initial activation. The algorithms or logic disclosed herein can help the pump assembly operate more efficiently and conserve power, for example but without limitation, battery power.
In any embodiments disclosed herein, the pump, circuit board or other controller, indicator lights, audible or visual alarms, and/or any other electronic components (collectively referred to herein as “pump electronics”) of the dressing embodiments disclosed herein can be powered by one or more batteries (for example, two batteries) and can weigh approximately 84 grams, or less than 90 grams, including the weight of the batteries. In some embodiments, the pump assembly can weigh less than 84 grams, including the weight of the batteries, or can weigh from approximately 80 grams to approximately 90 grams, from approximately 75 grams or less to approximately 100 grams, or between any values within the foregoing ranges. The weight and/or size of the pump assembly can be reduced by reducing the battery size and/or weight to, for example, AAA sized batteries, or smaller, or to one or more flat lithium batteries, or by using an array of batteries.
For example, in some embodiments, the pump can be powered by a single 1200 mAh lithium battery. A non-limiting example of a battery that would be suitable is a JAUCH LiMnO2 battery having a nominal voltage of 3.0 volts, a nominal capacity of 1200 mAh, a maximum continuous discharge current of 150 mA, a max pulse discharge current of 300 mA, a length of 40.0 mm, a width of 25.0 mm, a thickness of 5.0 mm, and a weight approximately 9.5 grams or less. The dimensions and/or weight of the battery can be reduced if a smaller capacity, voltage, and/or current is desired. For example, in any of the dressing embodiments disclosed herein, a plurality of lithium batteries can be used, each having a reduced size and weight as compared to the single battery described above. In any embodiments disclosed herein, any number of batteries (including any of the battery types disclosed herein) and/or capacitors can be positioned about the dressing cover layer and/or any of the dressing layers beneath the cover layer, the pump housing, and/or the conduit providing reduced pressure from the pump to the dressing, if such conduit is used. In any dressing embodiments, as described herein, the pump can be positioned directly on the dressing an configured such that no conduit is needed.
Any embodiments of the pump assembly and dressings disclosed herein can have a plurality of small capacitors, flexible batteries, and/or printed batteries supported by the dressing, the pump, and/or the conduit between the pump and the dressing, or otherwise. For example, an array of flat batteries can be distributed across the dressing cover layer, within the dressing layers under the cover layer (including being positioned across a plurality of the dressing layers), and/or across any conduit positioned on the dressing or between the pump and the dressing. Additionally, the weight and/or size of the pump assembly can be reduced by reducing the pump size and/or weight.
The batteries of any of the embodiments disclosed herein can be lithium chloride, lithium ion disulfide, lithium manganese dioxide or any other suitable batteries that are suitable for exposure to ethylene dioxide and/or other sterilization gases. Lithium air or zinc air batteries can also be used with any embodiment disclosed herein. Coin shaped or button shaped batteries of any composition can also be used with any embodiment disclosed herein. The batteries can be supported outside of the pump housing so as to minimize or eliminate the chance of an electrical spark which could cause an explosion in the presence of the sterilization gas or an explosive gas during the sterilization process when supported in the packaging element or elements. Additionally, where there are a plurality of batteries, the batteries can be spaced apart or otherwise separated in the packaging to prevent any power loss or sparking of the batteries during the sterilization process or otherwise before usage.
Additionally, in any embodiments disclosed herein, the power source for the pump can be provided by one or more flexible batteries. For example, one or more flexible printed batteries based on the technology developed by Imprint Energy and/or Solicore. For example, in any embodiments disclosed herein, the power source can comprise one or more lithium polymer batteries manufactured by Solicore, Inc. Solicore Flexion lithium polymer batteries are ultra-thin, flexible, and have a high energy density. For example, in some embodiments, the power source can have a plurality of thin, flexible lithium polymer batteries. In any embodiments disclosed herein, the power source can comprise a plurality of thin, flexible lithium polymer batteries each having a nominal capacity of approximately 10 to approximately 14 mAh or greater, and a voltage of approximately 3.0 V. In some embodiments, the batteries can each have a size of approximately 26 mm by approximately 29 mm, or approximately 49 mm by approximately 23 mm, and a thickness of approximately 0.45 mm.
In any embodiments disclosed herein, the power source can have from approximately 6 to approximately 10 flexible batteries, or from approximately 10 to approximately 50 or more flexible batteries, depending on the spatial area of the battery, having a thickness of approximately 0.5 mm or less. In any embodiments disclosed herein, the power source can have one or more batteries having a thickness of approximately 0.5 mm or less, or approximately 0.45 mm or less, and can be configured to have a total nominal capacity of from approximately 1000 mAh or less to approximately 1200 mAh.
Additionally, in any embodiments disclosed herein, the power can be provided by one or more carbon zinc flexible batteries manufactured by Blue Spark Technologies, built on 1.5V carbon-zinc battery chemistry. Voltages above 1.5V can be provided to the pump embodiments by providing multiple battery cells in series. Providing one or more flexible batteries in parallel can increase the total capacity of the power provided by the plurality of batteries. The Blue Spark Technologies ST series printed batteries can provide peak drain currents of approximately at least 1 mA. Such batteries can have a thickness of less than 500 micron (0.020 in). For example, the Blue Spark Technologies 110-ST1 battery provides 1.5V, has a capacity of 30 mAh, a peak drain current of 1-2 mA, a height of 55 mm (2.17 in), a length of 47 mm (1.87 in), and a thickness of 750 microns (0.029 in). The Blue Spark Technologies 111-ST1 battery provides 1.5V, has a capacity of 54 mAh, a peak drain current of 1-2 mA, a height of 78.7 mm (3.10 in), a length of 47.6 mm (1.87 in), and a thickness of 750 microns (0.029 in). The Blue Spark Technologies 111-ST1 battery provides 1.5V, has a capacity of 37 mAh, a peak drain current of 1-2 mA, a height of 79 mm (3.10 in), a length of 47 mm (1.87 in), and a thickness of 500 microns (0.020 in).
Any of the foregoing printed batteries, or similar printed batteries, can be used to provide a power source to any of the pump electronics of any of the dressing embodiments disclosed herein. Additionally, any of the batteries, including the flexible batteries, disclosed herein can be formed in a flat, planar relaxed shape, curved relaxed shape, or any other desired shape. Though not required, in any embodiments disclosed herein, the power source (including the thin, flexible batteries) can be positioned or distributed over or within the dressing absorption, transmission, and/or backing layers, positioned about the housing for the pump assembly, and/or positioned about the one or more layers comprising the conduit (if any) between the pump assembly and the dressing absorption, transmission, and/or backing layers.
Further, as in any of the dressing kit embodiments disclosed herein, the dressing kits can be configured such that the conductive connections between the power source and the pump assembly can be separated by a pull tab, isolation tab, activation switch, or other isolation mechanism to prevent any power supply from being provided to the pump assembly during sterilization, shipment, or handling prior to initiation of the negative pressure therapy.
In some embodiments, the pump assembly can be configured such that the battery connections or terminals have polarity protection. For example and without limitation, one or more of the battery contacts can be configured to have plastic or other non-conductive protrusions adjacent to the battery terminal contacts to inhibit the contact between the battery contact and the incorrect side of a battery that is inserted into the battery compartment in the incorrect orientation. In some embodiments, the one or more protrusions can be sized and configured to prevent the negative side of a standard cylindrical battery from contacting the battery contact adjacent to the one or more protrusions, while permitting a positive side of such battery to contact the battery contact. Generally, with this configuration, the battery can generally only make contact with the contact if the battery is inserted in the battery compartment in the correct orientation, thereby providing polarity protection to the pump assembly. Alternatively or additionally, a control board of the pump assembly can be configured to have polarity protective features or components. Additionally, a control board of the pump assembly can have one or more fuses to protect against overpower conditions or surge power conditions.
Additionally, any of the dressing embodiments disclosed herein can have one or more photovoltaic cells configured to provide energy to the pump electronics. Though not required, the embodiments having one or more photovoltaic cells can additionally have one or more batteries or capacitors configured to provide energy to the pump electronics. The photovoltaic cells, batteries, capacitors, and/or other suitable power sources of any of the dressing kit embodiments disclosed herein can be positioned about at least one of the dressing cover layer, the pump housing, and the conduit between the pump housing and the dressing cover layer.
In any embodiments disclosed herein, the conduit can have a plurality of articulations in along the length thereof, configured to bias the conduit to a shorter length state. The conduit can be extended if increased length is needed. Additionally, in some embodiments, a connector (or first connector) can be positioned at an end portion of the conduit to connect the conduit to a mating connector (or second connector) on the dressing. In some embodiments, the connector can be configured to activate the pump once the connector is attached to a mating connector fixed to the dressing.
For example and without limitation, in some embodiments, the dressing kit can have a pair of wires or electrical conductors extending from the pump assembly to the first connector. The two conductive wires or electrical conductors can form an open circuit along the length of the conduit. A low voltage can be provided through one of the two conductive wires, sufficient to activate the pump when the two conductive wires are in communication with one another. The two electrical conductors can terminate in a first set of electrical contact points. A second connector supported by the dressing can be configured to engage the first connector and can have a second set of electrical contact points. The second contact points can be electrically connected such that, when the first connector is fully engaged with the second connector supported by the dressing, the first set of contact points will be in contact with the second set of contact points, and close the circuit between the two conductive wires in the conduit to activate the pump.
Some embodiments of the pump assembly can be configured to abate noise and/or vibration of the pump during operation. Noise canceling chips can be used in some embodiments to reduce noise. In some embodiments, the pump output can be configured to ramp in and ramp out or gradually increase and decrease to eliminate sudden changes in the operation of the pump, thereby minimizing or eliminating any sudden transitions. Additionally, in any of the embodiments disclosed herein, the pump assembly or pump motor can be supported within a silicone or foam envelop or layer to attenuate vibration and noise.
Additionally, in any of the embodiments disclosed herein, the pump assembly or dressing member can be configured to support an organic light emitting diode (“OLED”) display or other suitable interface display.
Some of the embodiments comprise a pump and/or a pump and dressing kit. Some embodiments are directed to a pump and/or pump and dressing kit that have been sterilized before delivery to the hospital, operating room or theatre, or to the medical practitioner using such devices such that the sterile pump and/or a sterile pump/dressing kit can be applied immediately following the surgical or operating procedures. One advantage of this is that the surgeon can release the patient from the operating room knowing that the reduced pressure pump is operating and that the reduced pressure therapy has been started at the earliest point in time possible. A further advantage of applying the dressing kit immediately following the surgical or other procedure is that doing so can reduce the chance of infection by eliminating a subsequent dressing change that may otherwise be required in the ward. In other words, for those patients where a dressing (but not a pump) is applied in the operating theatre and then a problem is found thereafter, such as a leak or other issue with the dressing, if the dressing is required to be removed to be repositioned, replaced, or otherwise after the patient is released from the operating theater, the patient's wound can be exposed to infection risk when the dressing is repositioned, replaced, or otherwise outside of the operating theater. However, with the embodiments disclosed herein, if the pump is applied and tested while the patient is in the operating theater, any issues with the dressing that may require the dressing to be removed, repositioned, or otherwise, can be handled in the sterile operating room environment, thereby significantly reducing or eliminating the risk of exposure to pathogens, bacteria, or other contaminants. Further, it is generally not possible for a hospital to sterilize a traditional pump once it has been received by the hospital, and therefore the hospital may resort to bagging the pumps in sterile bags but risk compromising the operating room sterile field with this approach, particularly once the device is turned on and pathogens, bacteria, or other contaminants that may be inside the pump are release due to the operation of the pump.
In some embodiments, the pump can be configured to be amenable to gas sterilization, having features, components, and other characteristics that make the pump amenable to full sterilization gas exposure and penetration throughout the components of the pump. For example, without limitation, one or more pump valves have been selected or configured to permit a sufficient flow of sterilization gas therethrough such that the entire fluid pathway within the pump can be exposed to the sterilization gas. As will be explained in greater detail below, in some embodiments, the pump can have other components, such as without limitation, strategically positioned one way flow valves, to complement the other valves within the pump, which can improve the efficiency of the pump by reducing leakage through the flow pathway within the pump assembly.
Additionally, where provided, the sterile pump/dressing kit can also be designed and configured to be amenable to gas sterilization. As described below, the sterile pump/dressing kit can be configured such that all of the components comprising the sterile pump/dressing kit, including the pump assembly, are packaged together in at least a first packaging element before sterilization, permitting all of the components to be sterilized together. Furthermore, as will be described, the components comprising the sterile pump/dressing kit can be arranged in the packaging such that at least some of the components can be removed in a predefined order, making it easier for the surgeon or medical practitioner to assemble and apply the dressing to the patient.
There are a number of benefits to being able to begin treatment of a wound in the operating theater, including without limitation providing a substantially sealed barrier over the wound while the wound is in a sterile condition and environment that will inhibit or prevent bacteria or other contaminants from getting into the wound. Additionally, initiating the reduced pressure treatment at the earliest stage possible is also advantageous to healing of the wound.
The housing of any of the pump assembly embodiments can be configured such that a sterilization gas, such as ethylene dioxide, can penetrate into the housing such that the internal components of the pump assembly are exposed to the sterilization gas during normal sterilization processes. Typically, the pump will be exposed to the sterilization gas in a chamber that has been substantially evacuated of air or any other gas, so that the sterilization gas is drawn into the pump housing and into the other spaces and chambers within the pump assembly. For example, some embodiments of the pump housing can have an unsealed gap surrounding the connector through which the sterilization gas can pass. Also, in some embodiments, the first housing member can be joined to the second housing member without the use of a seal therebetween, and the pump assembly can have one or more valves that permit a sufficient amount of sterilization gas therein to effectively sterilize all of the internal components of the pump.
In some embodiments, the pump assembly can be mounted to any of the dressing embodiments disclosed herein and can have any suitable pump components (including, without limitation, a standard off-the-shelf vacuum pump such as the Koge Electronics KPV8A-3A pump). Some embodiments of the pump can be approximately 37 mm (length)×20 mm (width)×8 mm (depth). In any of the embodiments disclosed herein, one or more of the pumps can be a piezoelectric pump or a diaphragm pump or any other suitable pump. Additionally, in some embodiments, the pump can be a voice coil actuated pump.
The batteries can be lithium or zinc air activatable batteries, though not so required. If the dressing kit is to be sterilized, the batteries can be separated during the sterilization process by positioning a non-conductive barrier between the batteries. Additionally, to accommodate current legislation regarding battery disposal, some embodiments of the pump assembly can be configured such that the batteries are easily removable or separable from the dressing, for example before the dressing is removed from the body, for disposal after the dressing kit and pump assembly have been used.
In some embodiments, the pump can be configured such that the pump needs to be powered on at the start of the treatment cycle. Additionally, the pump can be configured such that the pump needs to be re-started when a leak is detected and dressing has been assessed. Regarding leaks, the pump assembly and dressing kit can be configured such that the device provides the following operation indications, without limitation: communication of device operating correctly; communication of leak being found; communication indicating that the dressing is full; and/or communication of a low or dead battery. The pump can be configured to communicate in multiple different languages. Any embodiments of the pump disclosed herein can be configured to communicate in 19 or more different languages. Any embodiments of the pump disclosed herein can be configured to maintain reduced pressure in the wound site between approximately 60 and approximately 80 mmHg, or between approximately 60 and approximately 130 mmHg.
Any of the embodiments illustrated in
In some embodiments, the power source 52 can be positioned along the short edge of the dressing 54 and the pump assembly 52 can be positioned along the long edge of the dressing 54, or vice versa. In any of the dressing embodiments disclosed herein, a control board and/or user interface, which can include operation buttons, visual displays, alarms, indicator lights, or otherwise, can be positioned in any desired position on the dressing, including above or below the backing layer (the backing layer being the outermost dressing layer), integrated within the dressing layers positioned beneath the backing layer, or otherwise.
As further illustrated by
Though not required, in some embodiments, the pump assembly can be positioned on one end of the dressing and the batteries or other power source can be positioned on another side or end of the dressing, such as the opposite side. This arrangement can result in a more balanced dressing in terms of weight, rigidity, and/or size.
In some embodiments, as with the dressing kit 70 embodiment illustrated in
In any of the dressing kit embodiments disclosed herein (which includes the pump embodiments supported remote to the dressing, such as adjacent to the dressing), the PCB or pump controller can be a flexible circuit board and/or can have one or more flexible components. A flexible circuit board is generally a patterned arrangement of printed circuitry and components that utilizes flexible based material with or without flexible overlay. These flexible electronic assemblies can be fabricated using the same components used for rigid printed circuit boards, but allowing the board to conform to a desired shape (flex) during its application. In their simplest form, flexible circuits are PCBs made of materials that allow for a non-planar positioning within the end product. Typical materials a polyimide-based, and can go under trade names such as Kapton (DuPont). Additionally, any of the control boards or controllers disclosed herein can have a combination of flexible and rigid substrates laminated into a single package.
Additionally, in any embodiments, the circuit boards can be printed on any desired substrate, including printing the circuits on one or more surfaces of the pump housing, on one or more dressing layers or surfaces, on one or more conduit and/or port layers or surfaces, or any combination of the foregoing.
In any of the dressing embodiments disclosed herein, with reference to
Additionally, in any embodiments disclosed herein, a hinge (such as a living hinge) can be positioned between the various components comprising the pump assembly, such as between a control board and the pump motor 72, or between an power source 76 and the pump 72, to improve the flexibility of the pump assembly and/or dressing kit. Printed connectors could be used to provide electrical connections between the PCB and the pump motor 72 and/or between the batteries 76 and the PCB or pump motor 72. Additionally, in any embodiments disclosed herein, if both the pump assembly 72 and the batteries 80 are positioned at one end of the dressing 70, a foam handle could be positioned at the other end to improve the handleability of the dressing 70.
As illustrated in
With reference to
The power source 112 (which can have one or more batteries) and pump assembly 114 can be separated, as shown in
With reference to
As shown in
With reference to
As such, any dressing member disclosed herein can be configured to have at least a first portion and a second portion configured to be separable from the first portion by hand and without the use of tools. The dressing member can be configured to be torn by hand to separate the first portion from the second portion. Additionally, positioning the pump 172 and power source (e.g., batteries) adjacent to the wound site instead of over the wound site can improve the comfort to the user by preventing the pump assembly and/or power source from contacting the sensitive wound bed. The dressing 174 can have at least one continuous layer that covers the entire dressing 174. The dressing member 174 can be approximately air-tight adjacent to the perforations or boundary between the first and second portions so that, upon separation of the second portion from the first portion of the dressing, no air leaks result.
In some embodiments, one or more cutouts 198 can be formed in the dressing between the first portion 192a and the second portion 192b to improve the flexibility of the dressing and to permit better articulation of the dressing. In this configuration, the dressing can have a narrowed or necked portion between the first and second portions. In some embodiments, a perforation 200 can be formed in the dressing 192 to permit separation of the first portion from the second portion of the dressing 192. This can facilitate the separation of the power source 196 from the rest of the dressing upon termination of the treatment for disposal of the two portions.
Alternatively, with reference to
In the embodiment illustrated in
Additionally, in some embodiments, the pump can be directly positioned on top of the wound contact layer, but have a port in communication with the 3D knitted and/or fabric layer so as to provide a source of negative pressure directly to the 3D knitted and/or fabric layer. As mentioned above, a liquid filter or liquid barrier can be positioned between the pump 232 and the 3D knitted and/or fabric layer to prevent liquid from entering the pump. In any of these embodiments, an absorption layer (which can be a superabsorbing layer) can be positioned above the 3D knitted and/or fabric layer or other transmission layer and can be configured to wick fluid out of the 3D knitted and/or fabric layer or other transmission layer.
The pump assembly 232 and/or batteries 234 can be positioned at an edge portion of the dressing 238, as illustrated in
Additionally, in any embodiments, the pump can be positioned in a depression formed in the absorption layer so as to be positioned directly on top of the transmission layer. A port in the pump can be positioned so as to be in communication with the absorption layer so that negative pressure is applied directly to the absorption layer. Some embodiments can have a perforated or permeable polymeric film between the absorption layer and the transmission layer, such as a polyurethane or polyethylene layer.
Further, in any embodiments disclosed herein, the pump can be positioned directly over the transmission layer (which can be a 3D knitted and/or fabric layer, or any other suitable transmissive material), either embedded within one or more absorption layers or positioned adjacent to one or more absorption layers. In such arrangements, an impermeable film can be positioned between the transmission layer and the absorption layer, surrounding the pump. The pump can be configured to apply negative pressure directly to the transmission layer and to draw liquid from the transmission layer through the pump and exhaust such liquid into the absorption layer. An impermeable backing layer can be, but is not required to be, positioned over the pump assembly. In any arrangements wherein the pump is located under the backing layer, a filtered or unfiltered exhaust port can be formed in the backing layer to ensure that gas can be exhausted from the dressing. In some embodiments, a bacteria, pathogen, or other contaminant filter can be positioned within the pump assembly.
In any dressing kit embodiments disclosed herein, the 3D knitted and/or fabric layer can have any of the properties of any of the dressing layers disclosed in U.S. Patent Application Publication No. 2011/0282309 (Ser. No. 13/092,042), (titled WOUND DRESSING AND METHOD OF USE), filed Apr. 21, 2011, and/or PCT Patent Application Publication No. WO 2011/087871 (International Patent Application No. PCT/US2010/061938), (titled APPARATUS AND METHODS FOR NEGATIVE PRESSURE WOUND THERAPY), filed internationally on Dec. 22, 2010, which applications are hereby incorporated by reference as if fully set forth herein.
The power source for any of these embodiments can be positioned within the pump assembly housing, can be positioned adjacent to the pump assembly housing and supported by the dressing, either within or above the absorptive layers adjacent to or apart from the absorptive layers, can be positioned on top of the absorptive layers, or can be positioned in a remote position apart from the pump assembly. With reference to
Further, any of the dressing kit embodiments disclosed herein can have an exhaust filter downstream of the pump assembly. The exhaust filter can be configured to prevent the spread of any bacteria, pathogens, or other harmful constituents from leaving the dressing through the exhaust port in the dressing kit. The exhaust filter can be supported by the pump assembly, or supported by any other layer or component of the dressing kit. For example, with reference the embodiment illustrated in
In any of the embodiments disclosed herein, including without limitation the embodiments illustrated in
For example, with reference to
This arrangement can reduce the profile of the pump assembly and/or the one or more batteries and improve the flexibility of the pump assembly and the one or more batteries. This can be produced in a single molding with internal components held captive between the one or more dressing layers and the upper casing of the pump assembly and/or the one or more batteries or between very thin layers within the pump assembly and the one or more batteries. The dressing kit illustrated in
Additionally, in some embodiments, as illustrated in
Alternatively, the conduit 277 can be adhered to the top of the dressing 272 around a perimeter of the dressing and/or transmission layers 273 using adhesive or any other suitable mechanism that will removably secure the conduit 277 in the desired location, but permit a medical practitioner or user to remove a desired length of conduit 277 from the coil so as to position the pump assembly 274 at any desired position either on the dressing 272 or remote to the dressing 272. In any embodiments disclosed herein, the pump assembly 274 and power source 276 can be supported on a separate support member 280 so that the pump assembly 274 and the power source 276 can be positioned at any desired location either remotely relative to the dressing 272, adjacent to the dressing 272, or even on board the dressing 272. The support member 280 can have adhesive on a bottom surface thereof for each into any desired surface, or any other desired fastening mechanism such as book and loop connectors, snaps, wires, or otherwise. Additionally, as described above, a flexible hinge 282 can be positioned between the pump assembly 274 and the power source 276 to increase the flexibility and conformability of the support member 280. Any of the dressing kit embodiments disclosed herein can have a similar arrangement of conduit as disclosed for the dressing kit 270, or any of the other features, details, or configurations disclosed were shown for dressing kit embodiment 270.
Additionally or alternatively, any of the embodiments disclosed herein of the dressing 292 can also have additional cutouts 295 formed in the dressing 292 to the outside of the pump assembly 294 and/or the power source 296 to also increase the flexibility and conformability of the dressing. As mentioned, this arrangement can improve the conformability and flexibility of the dressing and enable the pump assembly 294 and/or the power source 296 to better mold around a curved body surface. Additionally, in some embodiments, this arrangement can have a pinpoint hinge rather than a lengthwise hinge to permit the components to better mold over curved or complex surface contours. Any of the dressing kit embodiments disclosed herein can have the pump assembly and the power source arranged on the dressing in this configuration, and can have a dressing of this shape.
Additionally, in any embodiments disclosed herein, for example,
Additionally, as with any other embodiments disclosed herein, one or more press studs 346 can be supported on an outside surface of the cover layer of the dressing 332, the press studs being configured to receive complementary fastening features on the power source 346 and/or the pump assembly 334. In some embodiments, as is illustrated in
In some embodiments, a first snap connector 362a can engage a first female receiver 364a positioned on a housing for the pump assembly 354. Similarly, a second snap connector 362a can engage a second female receiver 364a positioned on housing for the power source 356. The first snap connector 362a can be electrically connected or in communication with the second snap connector 362b so that a current supplied from the power source connected to the second snap connector 362b can be communicated to the pump assembly through such electrical connection or wiring between the two snap connectors. Additionally, in any embodiments disclosed herein, the pump and battery module could have a hinge therebetween for added conformability and flexibility. A hinge could also be used to connect the pump and battery module to the dressing kit. Further, in any embodiments disclosed herein, the battery and the pump assembly can be separate modules that can be independently removed and/or replaced.
In any of the embodiments disclosed herein, the batteries can be positioned and supported apart from the dressing. The batteries can be secured to the body or to the dressing using tape, a local pad, snaps, a clip supported by the dressing, Velcro, and/or any other desired fastening member. The batteries can be inserted and removed to facilitate activation and deactivation of the pump, and to permit replacement and/or disposal of the batteries.
Additionally, in any embodiments disclosed herein, one or more press studs can be supported by the dressing. The one or more press studs can be configured to engage complementary connectors supported by the pump assembly and/or the one or more batteries to permit the pump assembly and/or the one or more batteries to be removably snap supported by the dressing. The stud connectors can also be used to create an electrical connection between one or more batteries and the pump assembly and, accordingly, can be used to activate the pump.
The press studs or snap connectors can allow the one or more batteries to be electrically disconnected from the pump assembly until one or both of the components is snapped into the snap connectors. Additionally, if there are two or more batteries, such batteries can also have stud type electrically conductive connectors that permit the batteries to be separately supportable by the dressing so that the power circuit can be completed by snapping each of the one or more batteries into the dressing. In this configuration, the batteries and/or pump assembly can be snapped into position following sterilization of the dressing kit. Such assembly can also serve to activate the pump.
Additionally, any of the dressing embodiments disclosed herein can be configured to support one or more power source modules or pump assemblies on or adjacent to the dressing. For example, having a multiple number of power sources (e.g., a plurality of batteries, or any combination of batteries, fuel cells, capacitors, and photovoltaic cells) can improve the flexibly and conformability of the dressing and can reduce the profile of the dressing. The dressing can be configured such that the batteries are replaceable or interchangeable with similar or different batteries, selectable depending on the duration of time the dressing is to be on the patient. In configurations wherein the power source is preferably removable, the power source can be snapped into the dock or otherwise removably attachable and detachable from the dressing and configured to be lifted out of the dock or otherwise removed from the dressing when it is time to either disposed of or replace the batteries or power source.
The batteries can be positioned within or supported by the docks prior to positioning the dressing on the patient's body. In embodiments using conductive connectors fixed to the dressing and or the pump assembly, starting or restarting the pump can be achieved by inserting or re-inserting the one or more batteries in the docks, so as to permit a user to control an operation of the pump by inserting or re-inserting the batteries.
In some embodiments, the hatch 379 can have one or more battery terminals or electrical connections thereon configured such that, during sterilization or before the pump is to be activated, the battery terminals are out of contact with the power source 376. After sterilization or before therapy is to be initiated, the hatch can be closed to create an electrical connection between the power source 376 and the pump assembly 374, thereby initiating the negative pressure wound therapy.
As an example, as illustrated in
With reference to
The dressing kit 430 embodiment of
Additionally, with reference to
In the embodiment of the dressing 490 illustrated in
With reference to the dressing kit 510 embodiment illustrated in
With reference to the dressing kit 530 embodiment illustrated in
Further, one or more batteries 556 can be supported in a removable cartridge or carrier 560 configured to be removably engageable with a housing 558 supported by the support layer 552. In some embodiments, the housing 558 can also support or surround the pump assembly 554 if desired. However, the pump assembly 554 can be separately supported by the support layer 552. The dressing kit 550 can be configured such that the power source can be removable and disposed of and/or replaceable with a replacement power source when desired. Any of the dressing kits disclosed herein can come with a first power source and a second power source that can be used sequentially.
With reference to
In some embodiments, as illustrated in
The battery and/or pump module can be loaded from the bottom to give the dressing a more integrated look and feel. Further, the device could be positioned beneath the backing layer (i.e., outermost layer away from the wound).
In some embodiments, the dressing kit 610 can be configured to have conductive terminals such that, when the power source 616 is engaged therewith or positioned within the opening 613, power is automatically provided to the pump assembly 614 from the power source 616 to either provide the power to the pump assembly 614 (but requiring a switch or button to activate the pump assembly) or to power and activate the pump assembly 614 to initiate negative pressure. A bottom layer 617 can be used to secure the housing and/or power source in the opening 613 on a bottom or base surface of the dressing member 612.
Multiple batteries or sources of power can be provided with the dressing kit 610. For example, a first battery pack 616 and a second battery pack 616 can be provided with the dressing kit 610 to provide interchangeable power sources. In some embodiments, the support member 618 can be attached directly to a dressing backing layer, or can be attached to a separate support layer, such as support layer 612, to enable the pump assembly and the power source to be attached adjacent to the wound and the dressing member positioned over the wound.
In some embodiments, the housing 618 can also support or surround the pump assembly 614 if desired. However, the pump assembly 614 can be separately supported by the support layer 612. The dressing kit 610 can be configured such that the power source can be removable and disposed of and/or replaceable with a replacement power source when desired. Any of the dressing kits disclosed herein can come with a first power source and a second power source that can be used sequentially. In some embodiments, the cover layer over the top of the dressing member 612 can form a continuous layer over the opening 613 such that a separate cover tab or layer 615 is not required. The cover layer over the top of the opening can be perforated or porous to permit air exhausted from the pump to exit the dressing.
In some embodiments, the dressing kit 630 can be configured to have conductive terminals such that, when the power source 636 is engaged therewith or positioned within the opening 633, power is automatically provided to the pump assembly 634 from the power source 636 to either provide the power to the pump assembly 634 (but requiring a switch or button to activate the pump assembly) or to power and activate the pump assembly 634 to initiate negative pressure.
Additionally, in some embodiments, multiple batteries or sources of power can be provided with the dressing kit 630. For example, a first battery pack 636 and a second battery pack 636 can be provided with the dressing kit 630 to provide interchangeable power sources. In some embodiments, as shown in
The pump assembly can also be supported within the opening 633 and can be covered by the cover layer 638. The cover layer 638 can be perforated to permit exhaust gas to exit the opening or compartment 633. In some embodiments, the cover layer over the top of the dressing member 632 can form a continuous layer over the opening 633 such that a separate cover tab or layer 638 is not required. The cover layer over the top of the opening can be perforated or porous to permit air exhausted from the pump to exit the dressing.
In some embodiments, the dressing kit 650 can be configured to have conductive terminals such that, when the support layer 658 is closed against the upper layer 653 of the dressing 652 on both sides of the power source 656, power is then provided to the pump assembly 654 from the power source 656 to either provide the power to the pump assembly 654 (but requiring a switch or button to activate the pump assembly) or to power and activate the pump assembly 654 to initiate negative pressure.
Additionally, in some embodiments, multiple batteries or sources of power can be provided with the dressing kit 650. For example, a first battery pack 656 and a second battery pack 656 can be provided with the dressing kit 650 to provide interchangeable power sources. The cover layer 658 can be perforated to permit exhaust gas to exit through the cover layer 658. In some embodiments, the cover layer over the top of the dressing member 652 can form a continuous layer over the opening 653 such that a separate cover tab or layer 658 is not required.
As illustrated in
Furthermore, in some embodiments, the dressing kit can have a tearable strap covering at least one of a pump assembly and a power source that can be perforated or slit to facilitate the tearing of the strap. Additionally, the strap could be non-tearable but could be adhered to the supporting surface using Velcro or other similar adhesive materials. With some embodiments of the pull-tab arrangement, the batteries can be removed by pulling on a label or pull tab. This can be achieved with either side or end ejection. As illustrated in
In some embodiments, the flexible battery 676 can have a plurality of different material layers coupled with one another. For example, in some embodiments, the flexible battery 676 can have a current collector layer 690, above an anode layer 692, followed by a separator layer 694, the cathode layer 696, and finally a current collector layer 698 on the bottom thereof. Additionally, any embodiments of the dressing kit disclosed herein can be powered by one or more flexible printed batteries based on the technology developed by Imprint Energy, or by one or more carbon zinc flexible batteries manufactured by Blue Spark Technologies, built, such as any of those described above. The size of the flexible battery 676 can depend on the power requirements of the pump assembly and duration desired for the negative pressure wound therapy. In some embodiments, however, the flexible battery 676 can be approximately the same size as the absorption layers in the dressing and can be configured to cover the absorption layers in the dressing.
Further, in any of the dressing kit embodiments disclosed herein, such as dressing kit 670, the pump assembly 674 can be controlled by a flexible control board. Further, any dressing kit embodiments disclosed herein can further have an organic light emitting diode (“OLED”) display or other suitable interface display.
In any embodiments disclosed herein, including the embodiment illustrated in
A flexible conduit 818 can communicate the negative pressure generated by the pump assembly 814 to the dressing member 812 and/or to the space between the dressing member 812 and the wound. In any embodiments disclosed herein, including the embodiment illustrated in
In any embodiments, the dressing layers 813, pump assembly 814, the power source 816, and the conduit 818 can be supported by the dressing member 812. Additionally, the conduit 818 can have any of the materials, features, or other details of any of the other conduit arrangements disclosed herein.
The dressing kit 830 can be configured such that the pump assembly 834 and the power source 836 can remain positioned adjacent to the dressing member 832 during treatment. Or, alternatively and at the user's preference, the pump assembly 834 and the power source 836 can be positioned on a portion of the dressing member 832 that can be detached from the portion of the dressing member 832 supporting the one or more absorption and/or transmission layers 833. For example, in some embodiments, the one or more absorption and/or transmission layers 833 can be positioned on a first portion 832a of the dressing member 812, and the pump assembly 834 and the power source 836 can be positioned on a second portion 832b of the dressing member 832 that can be detached from the first portion 832a of the dressing member 832. In some embodiments, the dressing member 832 can have a perforation, indentations, reduced thickness, or one or more cutouts between the first portion 832a and the second portion 832b of the dressing member 832 to facilitate the detachability of the first portion 832a from the second portion 832b of the dressing. This can facilitate the detachment of the second portion 832b of the dressing 832 from the first portion 832a of the dressing for placement of the second portion 832b of the dressing 832 in a desired location spaced apart from the first portion 832a of the dressing, and hence, spaced apart from the wound. The second portion 832b of the dressing member 832 can have a different adhesive thereon as compared to the adhesive on the first portion 832a of the dressing member 832 for adhesion to the skin or otherwise.
A flexible conduit 838 can communicate the negative pressure generated by the pump assembly 834 to the dressing member 832 and/or to the space between the dressing member 832 and the wound. A film layer adhered to a surface of the power source or the pump assembly, or a non-conductive material separating electrical connections between the power source and the pump assembly can be removed to activate the pump assembly.
In any embodiments disclosed herein, including the embodiment illustrated in
For example, in any dressing kit embodiments disclosed herein, the one or more absorption and/or transmission layers 853 can be positioned on a first portion 852a of the dressing member 812, and the pump assembly 854 and the power source 856 can be positioned on a second portion 852b of the dressing member 852 that can be detached from the first portion 852a of the dressing member 852. Additionally, in any embodiments disclosed herein, the conduit 858 can be positioned on a third portion 852c of the dressing member 852 that can be detached from the first portion 852a of the dressing member 852 and/or the second portion 852b of the dressing member 852.
In any embodiments, the dressing member 852 can have one or more intermittent or continuous scores, perforation, indentations, notches, cuts, cutouts, partial thickness cuts, or reduced thickness 855 between the first portion 852a and the second portion 852b of the dressing member 852, between the second portion 852b and the third portion 852c of the dressing member 852, and/or between the first portion 852a and the third portion 852c of the dressing member 852 to facilitate the detachability of the first portion 852a from the second portion 852b of the dressing member 852. This can facilitate the detachment of the second portion 852b of the dressing member 852 from the first portion 852a of the dressing member for placement of the second portion 852b of the dressing 852 in a desired location spaced apart from the first portion 852a of the dressing, and hence, spaced apart from the wound. The second portion 852b of the dressing member 852 can have a different adhesive thereon as compared to the adhesive on the first portion 852a of the dressing member 852 for adhesion to the skin or otherwise. Further, as with any embodiments disclosed herein, the pump assembly 854 can have pull tabs or strips configured to activate the pump or permit the conduction of current from the power source to the pump assembly.
Additionally, as illustrated in
For example, in some embodiments, as illustrated in
Additionally, with reference to
In any embodiments disclosed herein, including the embodiment illustrated in
In any embodiments disclosed herein, the conduit can be formed of two layers of liquid and air impervious material (such as a thin polymer film) and have one or more layers of foam or other porous material to prevent the conduit from collapsing, formed in a circular, square, or other shaped length of material having foam or other porous material therein. As such, the dressing can be configured such that a user can adjust the length of the conduit by the amount of the conduit removed from the dressing.
Additionally, with reference to the dressing kit embodiment 870 illustrated in
In any of these arrangements, the conduit 878 can be unwound or extended to permit the user to select the appropriate length of the conduit 878. The dressing can be used in the completely wound up arrangement illustrated in
Additionally, the dressing can be configured such that a perforated or weakened band of material is routed around the portion of the dressing that supports the battery. This can form a detachable portion of the dressing that supports the battery. Such configurations can facilitate battery removal, replacement, and/or proper disposal. Additionally, the battery module can be supported on a removable or separate portion of the dressing that tape or otherwise adhered to the main portion of the dressing and is easily removed therefrom for easy disposal of the battery module. The portion of the dressing that can support the battery module can be connected to the remaining portion of the dressing by tape, a local pad, or otherwise. The pump can be supported by the main dressing area. This could have a benefit for sterilization or sterilization of particular parts of the dressing, and could permit frequent (e.g., daily) battery changes. Additionally, in some embodiments, the batteries can be supported in a battery tray that can be easily supported by the dressing. The battery tray can be configured to be snapped into and out of the receiving portion of the dressing or pump assembly. This can reduce the wall thickness of the battery module and battery compartment.
In the embodiment of the dressing kit 910 illustrated in
With reference to
In any dressing kit embodiments disclosed herein, the dressing kit can have one or more pull tabs (such as pull tabs 957 illustrated in
Additionally, in any embodiments, the packaging supporting the dressing kit can be configured such that such tab or isolator is fixedly positioned between the components in the electrical circuit to ensure that the batteries are not electrically connected to the pump assembly or other components during sterilization (if used) or prior to activation. For example, as illustrated in
As shown in
With reference to the dressing kit 990 shown in
The switch 1017 (which can be a trip switch) illustrated in
In some embodiments, the circuitry of the pump can be used to maintain the switch in the depressed state when the operating conditions under the backing layer are within threshold parameters. In some embodiments, the switch 1017 can have one or more components made from a shape memory material, or have a memory bistable dome or diaphragm therein that can hold the switch 1017 in a depressed position for a predetermined period of time during initial pump down until the level of reduced pressure under the overlay is sufficient to maintain the switch in the depressed (or second) position. In some embodiments, a pressure sensor within the dressing or pump assembly can be configured to provide a current of electricity to a shape memory, piezoelectric material sufficient to hold the switch in the depressed or second position.
The switch can be configured to pop up if there is a leak in the dressing (detected based flow rate through the pump or on duty cycle feedback or other parameters), or if one or more other parameters or conditions are not met, such as but not limited to insufficient battery power or insufficient negative pressure within the dressing after a predetermined period of time. For example, the switch of this or any other embodiment disclosed herein can be configured to move between a first on position and a second off position, and to remain in the first position when a threshold level of negative pressure is maintained beneath the backing layer. The switch of this or any other embodiment disclosed herein can be configured to move to the second position when the level of negative pressure under the backing layer is less than a threshold level of negative pressure and the pump assembly exceeds a threshold flow rate for a threshold period of time, which can be caused by the presence of a leak in the system. For example, any of the embodiments disclosed herein can be configured to trigger an alarm or change the switch or button from a first operational position to a second non-operational position when the pressure beneath the dressing is less than 60 mmHg (i.e., less meaning 59 mmHg or lower) and the pump assembly has been operating for a threshold period of time, such as for approximately 5 minutes, from approximately 5 minutes to approximately 8 minutes, or from approximately 2 minutes to approximately 5 minutes, or any values within any of the foregoing ranges. Additionally, depressing the switch can produce an audible click to alert the user that the switch has been activated.
The embodiment of the dressing kit 1030 illustrated in
Alternatively, in any embodiments, the activation switch can be a slide activation switch (such as slide activation switch 1057 illustrated in
Any of the embodiments disclosed herein wherein the activation mechanism has a sliding mechanism, a sliding switch, or other moving activation mechanism, including without limitation the embodiments illustrated in
For example, the dressing kit embodiments can be supported in the packaging such that, while the dressing kit is supported in the packaging, the components of the battery pack or pump assembly are held in a first or non-operational position and prevented from moving to a second operational position. In this configuration, when the components are in the first position, the pump is non-operational due to the fact that the battery terminals are not in contact with the one or more batteries. For example, the packaging supporting the dressing kit can prevent a lid of the battery housing from moving to the second position by holding the housing lid or cap in the first position. The packaging can have protrusions that are positioned between the housing lid or cap and the body of the battery housing that separate the battery housing lid from the body of the battery housing. Once the dressing kit is removed from the packaging, the battery housing lid or cartridge can be slid inward, permitting the terminals to contact the batteries so that the pump can be activated. In this configuration, the battery housing can serve as an activation button. Sliding the lid out of contact from the batteries can stop the operation of the pump. Further, the dressing kit can be configured such that sliding the batteries into engagement with the battery terminals will result in an audible click, to alert a user regarding the position of the components of the battery enclosure or regarding whether the battery circuit is open or closed.
Any of the dressing kit embodiments disclosed herein can have a rotating or wheel activation switch (such as the rotating switch 1117 illustrated in
Similarly, the pull tab 1137 in
Additionally, as mentioned, for any of the switches or buttons of any of the dressing kits disclosed herein, the pump assemblies and/or battery modules can be configured such that the position of the switch or button dictates the position of the batteries relative to the battery terminals or other electrical connections with the pump assembly. Further, as with any other embodiment disclosed herein, the packaging surrounding the dressing kit having the pull tab arrangement illustrated in
In any of the pull tab arrangements disclosed herein, with reference to
In any embodiments disclosed herein, as illustrated in
As mentioned, any of the dressing kit embodiments disclosed herein can have a visual pressure indicator configured to provide a visual indication of the pressure beneath the backing layer. The visual pressure indicator can be configured to change position in response to a differential in pressure between the space beneath the backing layer and atmospheric pressure. In some embodiments, the pressure indicator or bubble can be configured to retract or collapse toward the wound surface in response to increasing levels of reduced pressure beneath the backing layer.
In some embodiments, the pressure indicator can have a different color as compared to the remainder of the dressing, or can be configured to change color in response to threshold pressure differentials between the space beneath the backing layer and atmospheric pressure. The pressure indicator can be positioned in an opening or depression formed in the dressing to shield the pressure indicator from impact and to protect the pressure indicator. For example, as described above, the dressing kit 330 of
The one or more pressure indicators can be supported in any desired location on the dressing. With reference to
In some embodiments, the membrane can be substantially opaque except when in contact with the colored material or liquid 1276 beneath the membrane 1274. When the membrane 1274 contacts the liquid or solid material 1276 beneath the membrane 1274, the color of such liquid or solid material 1276 can become more visible such that the color becomes apparent when a threshold level of reduced pressure is exerted on the membrane 1274, causing it to more toward the colored material.
As mentioned, a colored material such as ink or other material can be positioned under the membrane. The dressing can be configured such that the membrane layer between the pressure bubble and the colored material is substantially more visible in the second state than in the first state, permitting the user to visually inspect the level of reduced pressure in the overlay by visually monitoring the color under the pressure bubble. In some arrangements, the pressure bubble can be visually observed after depressing the button.
Other pressure indicators can be supported by the wound dressing. For example, as illustrated in
The pressure indicators or bubbles can be mounted on a panel or formed in a panel arrangement and can have any suitable shape or size. The pressure indicators can be integrally formed with the overlay material, or can be integrally formed in a panel arrangement that can be attached to or mounted on the overlay. Additionally, the pressure indicators can be individually formed. In any embodiments disclosed herein, a pressure indicator can be positioned in each of four corners on the overlay.
With reference to
With reference to
As shown in
Further, as shown in
In any embodiments disclosed herein, as is shown for the embodiment of the dressing kit 1310 shown in
Additionally, with reference to
In any embodiments disclosed herein, at least the top layer or top surface of the packing material can be a different color than the other materials comprising the dressing. The dressing can be configured such that the color of the packing material is substantially only visible, or is visibly darker or different, when the dressing is in the second reduced pressure state than when it is in the first state.
With reference to
Any of the dressing kit embodiments disclosed herein can have a vibration buzzer 1352 that can be tethered to the dressing 1354 (as shown in
In any embodiments disclosed herein, the dressing can have one or more sensors therein that can trigger an alarm when a threshold level or when one or more predetermined levels of saturation within the dressing has been reached. For example, the dressing can be configured to trigger a first alarm when a first level of saturation has been reached, to trigger a second alarm when a second level of saturation has been reached, to trigger a third alarm when a third level of saturation has been reached, and so on, wherein the level of saturation is the level of fullness of the dressing. In some embodiments, the sensors can be positioned within the absorption layers of the dressing and can be configured to generate a signal based on exposure to liquid within the dressing. For example, one or more hygroscopic sensors could be positioned under the backing layer of the overlay. The sensors can be positioned within the dressing layers, and discrete locations about the dressing layers to monitor the amount of liquid throughout the dressing layers. For example, in any embodiments disclosed herein, between 2 and 4 sensors can be positioned symmetrically about the dressing layers, or between 4 and 6 sensors can be positioned symmetrically about the dressing layers. Some embodiments of the dressing kit can have one sensor positioned under the backing layer. In any embodiments disclosed herein, one or more sensors can be positioned adjacent to the port to the pump assembly. Without limitation, the first level can be at approximately 60% saturation, the second level can be at approximately 75% saturation, and the third level can be at approximately 90% saturation. In some embodiments, the first level can be from approximately 60% saturation to approximately 70% saturation, the second level can be from approximately 70% saturation to approximately 80% saturation, and the third level can be from approximately 80% saturation to approximately 90% saturation. In some embodiments, the saturation level can be detected using one or more resistance or capacitance sensors (such as a humidity or moisture sensor based on resistivity or capacitance) positioned within the dressing. In any embodiments disclosed herein, the moisture sensor can be positioned close to or adjacent the wound facing side of the filter or otherwise adjacent to the pump assembly or port to indicate the dressing is saturated or the fluid level is close to the level that will result in blockage to the filter, which could inhibit further negative pressure transmission from the pump assembly.
In any of the embodiments disclosed herein, with reference to
Similarly, with reference to
As illustrated in
With reference to
With reference to
With reference to the embodiment depicted in
In some embodiments, such as the embodiment of the noise attenuating system 1510 illustrated in
With reference to
In some embodiments, the support handle member 1551 can have a first lengthwise portion 1551a and a second lengthwise portion 1551a positioned between the dressing layers 1553 and an outer perimeter 1552a of the dressing member 1552. In some embodiments, the first and second lengthwise portions 1551a can be interconnected. Additionally, the support handle member 1551 can have a first end portion 1551b and a second end portion 1551b positioned between the dressing layers 1553 and an outer perimeter 1552a of the dressing member 1552. In some embodiments, the first and second end portions 1551b can be interconnected. Additionally, in some embodiments, the support handle member 1551 can have a housing or third portion 1557 configured to cover an end portion of the dressing member 1552. For example, one or more buttons, switches, a pump assembly, a power source, and/or other features can be protectably supported under the third portion 1557 of the support handle member 1551. The support handle member 1551 can be configured to activate the pump upon removal. In some embodiments, the support handle member can be continuous such that each portion is interconnected.
Features, materials, characteristics, or groups described in conjunction with a particular aspect, embodiment, or example are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The protection is not restricted to the details of any foregoing embodiments. The protection extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
While certain embodiments have been described, these embodiments have been presented by way of example only, and are not intended to limit the scope of protection. Indeed, the novel methods and systems described herein may be embodied in a variety of other forms. Furthermore, various omissions, substitutions and changes in the form of the methods and systems described herein may be made. Those skilled in the art will appreciate that in some embodiments, the actual steps taken in the processes illustrated and/or disclosed may differ from those shown in the figures. Depending on the embodiment, certain of the steps described above may be removed, others may be added. Accordingly, the scope of the present disclosure is intended to be defined only by reference to the appended claims. The accompanying claims and their equivalents are intended to cover such forms or modifications as would fall within the scope and spirit of the protection. Furthermore, the features and attributes of the specific embodiments disclosed above may be combined in different ways to form additional embodiments, all of which fall within the scope of the present disclosure. Although the present disclosure provides certain preferred embodiments and applications, other embodiments that are apparent to those of ordinary skill in the art, including embodiments which do not provide all of the features and advantages set forth herein, are also within the scope of this disclosure. Accordingly, the scope of the present disclosure is intended to be defined only by reference to the appended claims.
Further embodiments of this patent application include the embodiments described in U.S. patent application Ser. No. 13/092,042, filed on Apr. 21, 2011. These embodiments are described further below, with reference to the figures from this application that are incorporated by reference herein.
FIG. 3 of U.S. patent application Ser. No. 13/092,042 shows a plan view of a wound dressing including baffle elements that reduce the rate at which wound exudate moves towards the orifice according to one embodiment of the invention. The wound dressing illustrated in FIG. 3 of U.S. patent application Ser. No. 13/092,042 is similar to that shown in FIGS. 1 and 2 of U.S. patent application Ser. No. 13/092,042, but includes a number of baffle elements 310 disposed across the central raised region 201. The baffle elements 310 form barriers in the central region of the dressing, which arrest the movement of wound exudate towards the orifice.
Embodiments of baffle elements that may be used in the wound dressing described herein are preferably at least partly flexible, so as to permit the wound dressing to flex and conform with the skin of the patient surrounding the wound site. When so present in the wound dressing, the baffle elements are preferably constructed so as to at least partially prevent liquid from flowing directly to the wound dressing port or orifice and its associated filter, if so provided. The baffle elements thus increase the distance that liquids may require to reach the port, which may help in absorbing these fluids into the absorbent or superabsorbent material of the wound dressing.
According to some embodiments of the invention, the baffle element may comprise a sealing region in which the absorbent layer 110 and transmission layer 105 are absent and cover layer 140 is sealed to the wound contact layer 101. Thus, the baffle element presents a barrier to the motion of the wound exudate, which must therefore follow a path that avoids the baffle element. Thus the time taken for the wound exudate to reach the orifice is increased.
In some embodiments, the baffle elements may be an insert of a substantially non-porous material, for example a closed-cell polyethylene foam, placed inside the dressing. In some cases, it may be preferable to place such an inserted baffle element in a sealing region where one or more of the absorbent layer 110 and/or transmission layer 105 are absent. A sealant, for example a viscous curing sealant such as a silicone sealant, could be placed or injected as a thin strip so as to form a baffle element that is substantially liquid impermeable. Such a baffle element could be placed or injected into a region of the transmission layer 105 and/or absorbent layer 110, or also a sealing region where the absorbent layer 110 and/or transmission layer 105 are absent.
FIG. 6 of U.S. patent application Ser. No. 13/092,042 illustrates a wound dressing including a baffle element according to a further embodiment of the invention. A single baffle element 610 provides a cup shaped barrier between the bulk of the absorbent layer 110 and the orifice 145. Thus wound exudate that is initially drawn from the wound site within the region defined by the baffle element 610, must follow a path around the outside of the cup shaped barrier to reach the orifice 145. As will be recognized, the baffle element 610 reduces the effect of gravity on reducing the time taken for the wound exudate to move to the orifice 145, as for most orientations of the wound dressing at least a part of the path taken by the wound exudate will be against the force of gravity.
The embodiments of FIGS. 3 and 6 of U.S. patent application Ser. No. 13/092,042 have been described with respect to a wound dressing having a structure as shown in FIG. 1 of U.S. patent application Ser. No. 13/092,042. However, it will be understood that the baffle elements could equally be applied to a wound dressing in which the transmission layer 105 was absent.
FIG. 4 of U.S. patent application Ser. No. 13/092,042 shows a plan view of a wound dressing including the at least one element according to one embodiment of the invention in which a number of baffle elements 410 are provided that extend across the width of the central region 201 of the wound dressing, with further baffle elements 412 formed in a semi-circular path around the orifice 145.
FIG. 5 of U.S. patent application Ser. No. 13/092,042 illustrates the configuration of baffle elements 410 according to some embodiments of the invention. The baffle element comprises a channel of absorbent material 510 underlying the transmission layer 105. A channel in the absorbent layer 110 is located over the baffle element 410 so that the transmission layer is in contact with the cover layer 140 in the region of the baffle element 410. Thus, wound exudate that is moving along a lower surface of the transmission layer 105, and has therefore not been drawn into absorbent layer 110, will come into contact with and be absorbed by the channel of absorbent material 510.
Alternatively, or additionally, baffle elements may comprise one or more channels provided in the surface of the transmission layer 105 underlying and abutting the absorbent layer 110. In use, when negative pressure is applied to the wound dressing, the absorbent layer 110 will be drawn into the channel. The channel in the transmission layer may have a depth substantially equal to the depth of the transmission layer, or may have a depth less than the depth of the transmission layer. The dimensions of the channel may be chosen to ensure that the channel is filled by the absorbent layer 110 when negative pressure is applied to the wound dressing. According to some embodiments, the channel in the transmission layer comprises a channel of absorbent material in the transmission layer 105.
The baffle elements may be formed into a range of shapes and patterns, for example FIGS. 14A to 14L of U.S. patent application Ser. No. 13/092,042 illustrate wound dressings having a number of different exemplifying configurations of baffle elements. FIG. 14A of U.S. patent application Ser. No. 13/092,042 illustrates a linear baffle element in a vertical configuration aligned in the direction of the port or orifice. FIG. 14B of U.S. patent application Ser. No. 13/092,042 illustrates an X-shaped baffle element. FIGS. 14C-E of U.S. patent application Ser. No. 13/092,042 illustrate embodiments of wound dressings with multiple baffle elements, aligned in a generally diagonal, horizontal, or vertical manner.
FIG. 14F of U.S. patent application Ser. No. 13/092,042 illustrates baffle elements arranged in a six-armed starburst configuration, with a center portion left open. FIG. 14G of U.S. patent application Ser. No. 13/092,042 illustrates a W-shaped baffle element on the wound dressing in a position distal to the port or orifice. In FIG. 14H of U.S. patent application Ser. No. 13/092,042, an 3-by-3 array of X-shaped baffle elements is provided on the wound dressing, although it will be understood that more or less X-shaped baffle elements may be used. FIG. 141 of U.S. patent application Ser. No. 13/092,042 shows an embodiment with a plurality of rectangular baffle elements, and wherein one or more baffle elements are located underneath the port in the wound dressing. FIGS. 14J-K of U.S. patent application Ser. No. 13/092,042 illustrate wound dressing embodiments with longer diagonal and horizontal baffle elements. In FIG. 14L of U.S. patent application Ser. No. 13/092,042, rectangular baffle elements are present on this embodiment of a wound dressing, wherein the baffle elements are of different sizes.
This application is a continuation application of U.S. application Ser. No. 16/047,786, filed Jul. 27, 2018, which is a continuation application of U.S. National Stage Patent Application No. 14/385,136, filed on Sep. 12, 2014 and now U.S. Pat. No. 10,046,096, which claims priority to International Patent Application No. PCT/IB2013/000847, filed on Mar. 12, 2013, which claims priority benefit of U.S. Provisional Patent Application No. 61/609,905 filed Mar. 12, 2012, titled REDUCED PRESSURE APPARATUS AND METHODS. The benefit of priority is claimed under the appropriate legal basis including, without limitation, under 35 U.S.C. § 119(e). Additionally, further components and details of wound dressings, wound treatment apparatuses, and negative pressure wound treatment methods that may be used with any of the embodiments disclosed in this application are found in the following applications and/or patents, which are hereby incorporated by reference in their entireties as if fully set forth herein: U.S. Patent Application Publication No. 2011/0282309 (Ser. No. 13/092,042). (titled WOUND DRESSING AND METHOD OF USE), filed on Apr. 21, 2011; PCT Patent Application Publication No. WO 2011/087871 (International Patent Application No. PCT/US2010/061938), (titled APPARATUS AND METHODS FOR NEGATIVE PRESSURE WOUND THERAPY), filed internationally on Dec. 22, 2010; U.S. Patent Publication No. 2009/0123513 (Ser. No. 11/922,894) (titled ANTIMICROBIAL BIGUANIDE METAL COMPLEXES), filed on May 21, 2008; PCT Patent Publication No. WO/2011/135284 (International Patent Application No. PCT/GB11/000622) (titled WOUND DRESSING), filed internationally on Apr. 21, 2011; PCT Patent Publication No. WO/2011/144888 (International Patent Application No. PCT/GB11/000621) (titled WOUND PROTECTION), filed internationally on Apr. 21, 2011; PCT Patent Publication No. WO/2011/135285 (International Patent Application No. PCT/GB11/000625) (titled WOUND DRESSING), filed internationally on Apr. 21, 2011; PCT Patent Publication No. WO/2011/135286 (International Patent Application No. PCT/GB11/000626) (titled MULTIPORT DRESSING), filed internationally on Apr. 21, 2011; PCT Patent Publication No. WO/2011/135287 (International Patent Application No. PCT/GB11/000628) (titled SUCTION PORT), filed internationally on Apr. 21, 2011; PCT Patent Publication No. WO/2012/038724 (International Patent Application No. PCT/GB11/051745) (titled PRESSURE CONTROL APPARATUS), filed internationally on Sep. 16, 2011; U.S. patent application Ser. No. 13/287,897 (titled “REDUCED PRESSURE THERAPY APPARATUSES AND METHODS OF USING SAME,), filed on Nov. 2, 2011; and U.S. Patent Application Publication No. 2012/0136325 (Ser. No. 13/287,959), (titled SYSTEMS AND METHODS FOR CONTROLLING OPERATION OF A REDUCED PRESSURE THERAPY SYSTEM), filed on Nov. 2, 2011.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3874387 | Barbieri | Apr 1975 | A |
| 3972328 | Chen | Aug 1976 | A |
| 4224941 | Stivala | Sep 1980 | A |
| 4398910 | Blake et al. | Aug 1983 | A |
| 4468969 | Schwartz | Sep 1984 | A |
| 4534356 | Papadakis | Aug 1985 | A |
| 4569674 | Phillips et al. | Feb 1986 | A |
| 4624656 | Clark et al. | Nov 1986 | A |
| 4681562 | Beck et al. | Jul 1987 | A |
| 4767943 | Adler et al. | Aug 1988 | A |
| 4846164 | Martz | Jul 1989 | A |
| 4979944 | Luzsicza | Dec 1990 | A |
| 5055195 | Trasch et al. | Oct 1991 | A |
| 5055198 | Shettigar | Oct 1991 | A |
| 5056510 | Gilman | Oct 1991 | A |
| 5115801 | Cartmell et al. | May 1992 | A |
| 5152757 | Eriksson | Oct 1992 | A |
| 5160328 | Cartmell et al. | Nov 1992 | A |
| 5181905 | Flam | Jan 1993 | A |
| 5197945 | Cole et al. | Mar 1993 | A |
| 5238732 | Krishnan | Aug 1993 | A |
| 5266928 | Johnson | Nov 1993 | A |
| 5336219 | Krantz | Aug 1994 | A |
| 5354261 | Clark et al. | Oct 1994 | A |
| 5358494 | Svedman | Oct 1994 | A |
| 5364381 | Soga et al. | Nov 1994 | A |
| 5380294 | Persson | Jan 1995 | A |
| D357743 | Bilitz et al. | Apr 1995 | S |
| 5417743 | Dauber | May 1995 | A |
| 5447492 | Cartmell et al. | Sep 1995 | A |
| 5456660 | Reich et al. | Oct 1995 | A |
| 5480377 | Cartmell et al. | Jan 1996 | A |
| 5497788 | Inman et al. | Mar 1996 | A |
| 5527293 | Zamierowski | Jun 1996 | A |
| 5538500 | Peterson | Jul 1996 | A |
| 5549584 | Gross | Aug 1996 | A |
| 5562107 | Lavender et al. | Oct 1996 | A |
| 5579765 | Cox et al. | Dec 1996 | A |
| 5603946 | Constantine | Feb 1997 | A |
| 5636643 | Argenta et al. | Jun 1997 | A |
| 5637080 | Geng | Jun 1997 | A |
| 5643189 | Masini | Jul 1997 | A |
| 5662599 | Reich et al. | Sep 1997 | A |
| 5702356 | Hathman | Dec 1997 | A |
| 5704905 | Jensen et al. | Jan 1998 | A |
| 5713384 | Roach et al. | Feb 1998 | A |
| 5759570 | Arnold | Jun 1998 | A |
| 5779657 | Daneshvar | Jul 1998 | A |
| 5827213 | Jensen | Oct 1998 | A |
| 5833646 | Masini | Nov 1998 | A |
| 5840052 | Johns | Nov 1998 | A |
| 5843025 | Shaari | Dec 1998 | A |
| 5887437 | Maxim | Mar 1999 | A |
| 5897541 | Uitenbroek et al. | Apr 1999 | A |
| 5902256 | Benaron | May 1999 | A |
| 5964723 | Augustine | Oct 1999 | A |
| 6040493 | Cooke et al. | Mar 2000 | A |
| 6071267 | Zamierowski | Jun 2000 | A |
| 6075177 | Bahia et al. | Jun 2000 | A |
| 6124520 | Roberts | Sep 2000 | A |
| 6124521 | Roberts | Sep 2000 | A |
| 6142982 | Hunt et al. | Nov 2000 | A |
| 6168800 | Dobos et al. | Jan 2001 | B1 |
| 6183438 | Berguer | Feb 2001 | B1 |
| 6189327 | Strauss et al. | Feb 2001 | B1 |
| 6225523 | Masini | May 2001 | B1 |
| 6261276 | Reitsma | Jul 2001 | B1 |
| 6261283 | Morgan et al. | Jul 2001 | B1 |
| 6297423 | Schoenfeldt et al. | Oct 2001 | B1 |
| 6362390 | Carlucci et al. | Mar 2002 | B1 |
| 6398767 | Fleischmann | Jun 2002 | B1 |
| 6468295 | Augustine et al. | Oct 2002 | B2 |
| 6471982 | Lydon et al. | Oct 2002 | B1 |
| 6506175 | Goldstein | Jan 2003 | B1 |
| 6528696 | Ireland | Mar 2003 | B1 |
| 6586653 | Graeme, III et al. | Jul 2003 | B2 |
| 6599262 | Masini | Jul 2003 | B1 |
| 6607495 | Skalak et al. | Aug 2003 | B1 |
| 6613953 | Altura | Sep 2003 | B1 |
| 6626891 | Ohmstede | Sep 2003 | B2 |
| 6685681 | Lockwood et al. | Feb 2004 | B2 |
| 6706940 | Worthley | Mar 2004 | B2 |
| 6719742 | McCormack et al. | Apr 2004 | B1 |
| 6752794 | Lockwood et al. | Jun 2004 | B2 |
| 6762337 | Boukanov et al. | Jul 2004 | B2 |
| 6764459 | Donaldson | Jul 2004 | B1 |
| 6776769 | Smith | Aug 2004 | B2 |
| 6787682 | Gilman | Sep 2004 | B2 |
| 6794554 | Sessions et al. | Sep 2004 | B2 |
| 6800074 | Henley et al. | Oct 2004 | B2 |
| 6855135 | Lockwood et al. | Feb 2005 | B2 |
| 6936037 | Bubb et al. | Aug 2005 | B2 |
| 6942633 | Odland | Sep 2005 | B2 |
| 6951553 | Bubb et al. | Oct 2005 | B2 |
| 6979324 | Bybordi et al. | Dec 2005 | B2 |
| 6998511 | Worthley | Feb 2006 | B2 |
| 7004915 | Boynton et al. | Feb 2006 | B2 |
| 7022113 | Lockwood et al. | Apr 2006 | B2 |
| 7041057 | Faupel et al. | May 2006 | B1 |
| 7049478 | Smith | May 2006 | B1 |
| 7067709 | Murata et al. | Jun 2006 | B2 |
| 7070584 | Johnson et al. | Jul 2006 | B2 |
| 7087806 | Scheinberg et al. | Aug 2006 | B2 |
| 7108683 | Zamierowski | Sep 2006 | B2 |
| 7118545 | Boyde | Oct 2006 | B2 |
| 7216651 | Argenta et al. | May 2007 | B2 |
| 7294751 | Propp et al. | Nov 2007 | B2 |
| 7294752 | Propp | Nov 2007 | B1 |
| 7338482 | Lockwood et al. | Mar 2008 | B2 |
| 7361184 | Joshi | Apr 2008 | B2 |
| 7381859 | Hunt et al. | Jun 2008 | B2 |
| 7429689 | Chen et al. | Sep 2008 | B2 |
| 7476205 | Erdmann | Jan 2009 | B2 |
| 7498802 | Takahata | Mar 2009 | B2 |
| 7511187 | Kelly | Mar 2009 | B2 |
| 7524315 | Blott et al. | Apr 2009 | B2 |
| 7553306 | Hunt et al. | Jun 2009 | B1 |
| 7563940 | Kurata | Jul 2009 | B2 |
| 7569742 | Haggstrom et al. | Aug 2009 | B2 |
| 7576256 | Bjornberg et al. | Aug 2009 | B2 |
| 7605298 | Bechert et al. | Oct 2009 | B2 |
| 7611500 | Lina et al. | Nov 2009 | B1 |
| 7615036 | Joshi et al. | Nov 2009 | B2 |
| 7622629 | Aali | Nov 2009 | B2 |
| D605775 | Koch et al. | Dec 2009 | S |
| 7625362 | Boehringer et al. | Dec 2009 | B2 |
| D608007 | Arbesman et al. | Jan 2010 | S |
| 7645253 | Gura et al. | Jan 2010 | B2 |
| 7687678 | Jacobs | Mar 2010 | B2 |
| 7699823 | Haggstrom et al. | Apr 2010 | B2 |
| 7708724 | Weston | May 2010 | B2 |
| 7722582 | Lina et al. | May 2010 | B2 |
| 7723561 | Propp | May 2010 | B2 |
| 7749531 | Booher | Jul 2010 | B2 |
| 7759537 | Bishop et al. | Jul 2010 | B2 |
| 7759539 | Shaw et al. | Jul 2010 | B2 |
| 7775998 | Riesinger | Aug 2010 | B2 |
| 7776028 | Miller et al. | Aug 2010 | B2 |
| 7779625 | Joshi et al. | Aug 2010 | B2 |
| D625422 | Arbesman et al. | Oct 2010 | S |
| 7811269 | Boynton et al. | Oct 2010 | B2 |
| 7837673 | Vogel | Nov 2010 | B2 |
| 7838717 | Haggstrom et al. | Nov 2010 | B2 |
| 7846141 | Weston | Dec 2010 | B2 |
| 7896864 | Lockwood et al. | Mar 2011 | B2 |
| 7910791 | Coffey | Mar 2011 | B2 |
| 7922676 | Daskal et al. | Apr 2011 | B2 |
| 7922703 | Riesinger | Apr 2011 | B2 |
| 7935066 | Shives et al. | May 2011 | B2 |
| 7942866 | Radl et al. | May 2011 | B2 |
| 7959624 | Riesinger | Jun 2011 | B2 |
| 7964766 | Blott et al. | Jun 2011 | B2 |
| 7976519 | Bubb et al. | Jul 2011 | B2 |
| 7988673 | Wright et al. | Aug 2011 | B2 |
| 8007257 | Heaton et al. | Aug 2011 | B2 |
| 8007481 | Schuessler et al. | Aug 2011 | B2 |
| 8021253 | Dell et al. | Sep 2011 | B2 |
| 8021347 | Vitaris et al. | Sep 2011 | B2 |
| 8062272 | Weston | Nov 2011 | B2 |
| 8062273 | Weston | Nov 2011 | B2 |
| 8062331 | Zamierowski | Nov 2011 | B2 |
| 8080702 | Blott et al. | Dec 2011 | B2 |
| 8092436 | Christensen | Jan 2012 | B2 |
| 8092441 | Sugito | Jan 2012 | B2 |
| 8118794 | Weston | Feb 2012 | B2 |
| 8158844 | McNeil | Apr 2012 | B2 |
| 8162907 | Heagle | Apr 2012 | B2 |
| 8167869 | Wudyka | May 2012 | B2 |
| 8168848 | Lockwood et al. | May 2012 | B2 |
| 8188331 | Barta et al. | May 2012 | B2 |
| 8192409 | Hardman et al. | Jun 2012 | B2 |
| 8207392 | Haggstrom et al. | Jun 2012 | B2 |
| 8212100 | Moore | Jul 2012 | B2 |
| 8212101 | Propp | Jul 2012 | B2 |
| 8215929 | Shen et al. | Jul 2012 | B2 |
| 8241261 | Randolph et al. | Aug 2012 | B2 |
| 8252971 | Aali et al. | Aug 2012 | B2 |
| 8282611 | Weston | Oct 2012 | B2 |
| 8303552 | Weston | Nov 2012 | B2 |
| 8314283 | Kingsford et al. | Nov 2012 | B2 |
| 8323264 | Weston et al. | Dec 2012 | B2 |
| 8328858 | Barsky et al. | Dec 2012 | B2 |
| 8371829 | Jaeb et al. | Feb 2013 | B2 |
| 8372049 | Jaeb et al. | Feb 2013 | B2 |
| 8372050 | Jaeb et al. | Feb 2013 | B2 |
| 8403899 | Sherman | Mar 2013 | B2 |
| 8404921 | Lee et al. | Mar 2013 | B2 |
| 8409157 | Haggstrom et al. | Apr 2013 | B2 |
| 8409160 | Locke et al. | Apr 2013 | B2 |
| 8414519 | Hudspeth et al. | Apr 2013 | B2 |
| 8419696 | Wilkes | Apr 2013 | B2 |
| 8425478 | Olson | Apr 2013 | B2 |
| 8439894 | Miller | May 2013 | B1 |
| 8444612 | Patel et al. | May 2013 | B2 |
| 8449508 | Coulthard et al. | May 2013 | B2 |
| 8460255 | Joshi et al. | Jun 2013 | B2 |
| 8500776 | Ebner | Aug 2013 | B2 |
| 8529548 | Blott et al. | Sep 2013 | B2 |
| 8535296 | Blott et al. | Sep 2013 | B2 |
| 8545464 | Weston | Oct 2013 | B2 |
| 8569566 | Blott et al. | Oct 2013 | B2 |
| 8579872 | Coulthard et al. | Nov 2013 | B2 |
| 8603074 | Kagan | Dec 2013 | B2 |
| 8604265 | Locke et al. | Dec 2013 | B2 |
| 8628505 | Weston | Jan 2014 | B2 |
| 8641691 | Fink et al. | Feb 2014 | B2 |
| 8641693 | Locke et al. | Feb 2014 | B2 |
| 8663198 | Buan et al. | Mar 2014 | B2 |
| 8702665 | Locke et al. | Apr 2014 | B2 |
| 8715256 | Greener | May 2014 | B2 |
| 8764732 | Hartwell | Jul 2014 | B2 |
| 8791316 | Greener | Jul 2014 | B2 |
| 8795243 | Weston | Aug 2014 | B2 |
| 8795247 | Bennett et al. | Aug 2014 | B2 |
| 8795257 | Coulthard et al. | Aug 2014 | B2 |
| 8801685 | Armstrong et al. | Aug 2014 | B2 |
| 8808274 | Hartwell | Aug 2014 | B2 |
| 8814842 | Coulthard et al. | Aug 2014 | B2 |
| 8821458 | Locke et al. | Sep 2014 | B2 |
| 8829263 | Haggstrom et al. | Sep 2014 | B2 |
| 8834451 | Blott et al. | Sep 2014 | B2 |
| 8870837 | Locke et al. | Oct 2014 | B2 |
| 8915895 | Jaeb et al. | Dec 2014 | B2 |
| 8961496 | Locke et al. | Feb 2015 | B2 |
| 8974429 | Gordon et al. | Mar 2015 | B2 |
| 9050209 | Coulthard et al. | Jun 2015 | B2 |
| 9084845 | Adie et al. | Jul 2015 | B2 |
| 9089630 | Perkins et al. | Jul 2015 | B2 |
| 9168330 | Joshi et al. | Oct 2015 | B2 |
| 9198802 | Robinson et al. | Dec 2015 | B2 |
| 9254353 | Locke et al. | Feb 2016 | B2 |
| 9259558 | Tsai | Feb 2016 | B2 |
| 9265665 | Robinson et al. | Feb 2016 | B2 |
| 9265867 | Coulthard et al. | Feb 2016 | B2 |
| 9393354 | Freedman et al. | Jul 2016 | B2 |
| 9414968 | Heagle | Aug 2016 | B2 |
| 9421133 | Hu et al. | Aug 2016 | B2 |
| 9427505 | Askem et al. | Aug 2016 | B2 |
| 9446176 | Locke et al. | Sep 2016 | B2 |
| 9452088 | Shulman et al. | Sep 2016 | B2 |
| 9452245 | Jaeb et al. | Sep 2016 | B2 |
| 9770368 | Robinson et al. | Sep 2017 | B2 |
| 9795725 | Joshi et al. | Oct 2017 | B2 |
| 9814811 | Aalders et al. | Nov 2017 | B2 |
| 9907703 | Allen et al. | Mar 2018 | B2 |
| RE46778 | Peron | Apr 2018 | E |
| 10046096 | Askem et al. | Aug 2018 | B2 |
| 10384041 | Patel et al. | Aug 2019 | B2 |
| 10660994 | Askem et al. | May 2020 | B2 |
| 11730877 | Askem | Aug 2023 | B2 |
| 20010034499 | Sessions et al. | Oct 2001 | A1 |
| 20010051178 | Blatchford et al. | Dec 2001 | A1 |
| 20020019602 | Geng | Feb 2002 | A1 |
| 20020072733 | Flaherty | Jun 2002 | A1 |
| 20020110672 | Muratore-Pallatino et al. | Aug 2002 | A1 |
| 20020169405 | Roberts | Nov 2002 | A1 |
| 20030009122 | Veras | Jan 2003 | A1 |
| 20030045825 | Etheredge, III | Mar 2003 | A1 |
| 20030069563 | Johnson | Apr 2003 | A1 |
| 20030114818 | Benecke et al. | Jun 2003 | A1 |
| 20030117371 | Roberts et al. | Jun 2003 | A1 |
| 20030180341 | Gooch et al. | Sep 2003 | A1 |
| 20030199800 | Levin | Oct 2003 | A1 |
| 20030212357 | Pace | Nov 2003 | A1 |
| 20030212359 | Butler | Nov 2003 | A1 |
| 20040064132 | Boehringer et al. | Apr 2004 | A1 |
| 20040073151 | Weston | Apr 2004 | A1 |
| 20040076662 | Riesinger | Apr 2004 | A1 |
| 20040078011 | Stevens | Apr 2004 | A1 |
| 20040087884 | Haddock et al. | May 2004 | A1 |
| 20040106888 | Lutri et al. | Jun 2004 | A1 |
| 20040138602 | Rossen | Jul 2004 | A1 |
| 20040162512 | Liedtke et al. | Aug 2004 | A1 |
| 20040167482 | Watson | Aug 2004 | A1 |
| 20040243042 | Lipman | Dec 2004 | A1 |
| 20050012616 | Forster et al. | Jan 2005 | A1 |
| 20050015036 | Lutri et al. | Jan 2005 | A1 |
| 20050045461 | Sweetland et al. | Mar 2005 | A1 |
| 20050065471 | Kuntz | Mar 2005 | A1 |
| 20050119737 | Bene et al. | Jun 2005 | A1 |
| 20050131327 | Lockwood et al. | Jun 2005 | A1 |
| 20050137539 | Biggie et al. | Jun 2005 | A1 |
| 20050272142 | Horita | Dec 2005 | A1 |
| 20060003604 | Angerpointner | Jan 2006 | A1 |
| 20060009744 | Erdman et al. | Jan 2006 | A1 |
| 20060019144 | Hidaka et al. | Jan 2006 | A1 |
| 20060020234 | Chou et al. | Jan 2006 | A1 |
| 20060029650 | Coffey | Feb 2006 | A1 |
| 20060086598 | Sneek et al. | Apr 2006 | A1 |
| 20060107642 | Smith et al. | May 2006 | A1 |
| 20060122548 | Abrams | Jun 2006 | A1 |
| 20060192259 | Silverbrook | Aug 2006 | A1 |
| 20060206047 | Lampe et al. | Sep 2006 | A1 |
| 20060213527 | Argenta et al. | Sep 2006 | A1 |
| 20060259102 | Slatkine | Nov 2006 | A1 |
| 20070003604 | Jones | Jan 2007 | A1 |
| 20070055209 | Patel et al. | Mar 2007 | A1 |
| 20070078366 | Haggstrom et al. | Apr 2007 | A1 |
| 20070078467 | Mullen | Apr 2007 | A1 |
| 20070091614 | Kaisser et al. | Apr 2007 | A1 |
| 20070100308 | Miyairi | May 2007 | A1 |
| 20070128055 | Lee | Jun 2007 | A1 |
| 20070179460 | Adahan | Aug 2007 | A1 |
| 20070225663 | Watt et al. | Sep 2007 | A1 |
| 20070255187 | Branch | Nov 2007 | A1 |
| 20070265586 | Joshi et al. | Nov 2007 | A1 |
| 20070282236 | LaGreca | Dec 2007 | A1 |
| 20080021356 | Castello Escude et al. | Jan 2008 | A1 |
| 20080021395 | Yodfat et al. | Jan 2008 | A1 |
| 20080051716 | Stutz | Feb 2008 | A1 |
| 20080058691 | Sorensen | Mar 2008 | A1 |
| 20080082059 | Fink et al. | Apr 2008 | A1 |
| 20080167592 | Greer | Jul 2008 | A1 |
| 20080200906 | Sanders et al. | Aug 2008 | A1 |
| 20080278336 | Ortega et al. | Nov 2008 | A1 |
| 20080281297 | Pesach et al. | Nov 2008 | A1 |
| 20080306456 | Riesinger | Dec 2008 | A1 |
| 20090012484 | Nielsen et al. | Jan 2009 | A1 |
| 20090048556 | Durand | Feb 2009 | A1 |
| 20090114293 | Kanai et al. | May 2009 | A1 |
| 20090125004 | Shen et al. | May 2009 | A1 |
| 20090129986 | Wimberger-Friedl et al. | May 2009 | A1 |
| 20090166411 | Kramer et al. | Jul 2009 | A1 |
| 20090227935 | Zanella et al. | Sep 2009 | A1 |
| 20090227968 | Vess | Sep 2009 | A1 |
| 20090227969 | Jaeb et al. | Sep 2009 | A1 |
| 20090234306 | Vitaris | Sep 2009 | A1 |
| 20090234309 | Vitaris et al. | Sep 2009 | A1 |
| 20090240185 | Jaeb et al. | Sep 2009 | A1 |
| 20090275896 | Kamen et al. | Nov 2009 | A1 |
| 20090299251 | Buan | Dec 2009 | A1 |
| 20090299306 | Buan | Dec 2009 | A1 |
| 20090320611 | Vasarhelyi et al. | Dec 2009 | A1 |
| 20100022990 | Karpowicz et al. | Jan 2010 | A1 |
| 20100036334 | Heagle et al. | Feb 2010 | A1 |
| 20100055158 | Vitaris et al. | Mar 2010 | A1 |
| 20100068820 | Meathrel et al. | Mar 2010 | A1 |
| 20100084074 | McClernon et al. | Apr 2010 | A1 |
| 20100087767 | McNeil | Apr 2010 | A1 |
| 20100100160 | Edman et al. | Apr 2010 | A1 |
| 20100106120 | Holm | Apr 2010 | A1 |
| 20100106121 | Holm | Apr 2010 | A1 |
| 20100125234 | Smith | May 2010 | A1 |
| 20100125258 | Coulthard et al. | May 2010 | A1 |
| 20100137775 | Hu et al. | Jun 2010 | A1 |
| 20100160881 | Lin et al. | Jun 2010 | A1 |
| 20100174250 | Hu et al. | Jul 2010 | A1 |
| 20100195318 | Jones | Aug 2010 | A1 |
| 20100217177 | Cali et al. | Aug 2010 | A1 |
| 20100262091 | Larsson | Oct 2010 | A1 |
| 20100265649 | Singh et al. | Oct 2010 | A1 |
| 20100280469 | Hall et al. | Nov 2010 | A1 |
| 20100286607 | Saltzstein | Nov 2010 | A1 |
| 20100292632 | Mulvihill et al. | Nov 2010 | A1 |
| 20100305490 | Coulthard | Dec 2010 | A1 |
| 20100305526 | Robinson et al. | Dec 2010 | A1 |
| 20100318052 | Ha et al. | Dec 2010 | A1 |
| 20100324510 | Andresen et al. | Dec 2010 | A1 |
| 20110004172 | Eckstein et al. | Jan 2011 | A1 |
| 20110040578 | Ramsey | Feb 2011 | A1 |
| 20110052664 | Tennican et al. | Mar 2011 | A1 |
| 20110054285 | Searle et al. | Mar 2011 | A1 |
| 20110054421 | Hartwell | Mar 2011 | A1 |
| 20110092927 | Wilkes et al. | Apr 2011 | A1 |
| 20110098621 | Fabo et al. | Apr 2011 | A1 |
| 20110106030 | Scholz | May 2011 | A1 |
| 20110112492 | Bharti et al. | May 2011 | A1 |
| 20110118683 | Weston | May 2011 | A1 |
| 20110137222 | Masini | Jun 2011 | A1 |
| 20110178375 | Forster | Jul 2011 | A1 |
| 20110178451 | Robinson et al. | Jul 2011 | A1 |
| 20110218509 | Dontas | Sep 2011 | A1 |
| 20110224631 | Simmons et al. | Sep 2011 | A1 |
| 20110230849 | Coulthard et al. | Sep 2011 | A1 |
| 20110236265 | Hasui et al. | Sep 2011 | A1 |
| 20110236277 | Lee et al. | Sep 2011 | A1 |
| 20110245788 | Marquez Canada | Oct 2011 | A1 |
| 20110247636 | Pollack | Oct 2011 | A1 |
| 20110270182 | Breznock et al. | Nov 2011 | A1 |
| 20110282309 | Adie et al. | Nov 2011 | A1 |
| 20110292623 | Stanley | Dec 2011 | A1 |
| 20110305736 | Wieland et al. | Dec 2011 | A1 |
| 20120016322 | Coulthard et al. | Jan 2012 | A1 |
| 20120016323 | Robinson | Jan 2012 | A1 |
| 20120041399 | Blott et al. | Feb 2012 | A1 |
| 20120053541 | Yao et al. | Mar 2012 | A1 |
| 20120059294 | Schubert et al. | Mar 2012 | A1 |
| 20120065664 | Avitable et al. | Mar 2012 | A1 |
| 20120095426 | Visscher et al. | Apr 2012 | A1 |
| 20120101465 | McGuire, Jr. | Apr 2012 | A1 |
| 20120109034 | Locke et al. | May 2012 | A1 |
| 20120109083 | Coulthard et al. | May 2012 | A1 |
| 20120123311 | Weidemann-Hendrickson et al. | May 2012 | A1 |
| 20120172778 | Rastegar et al. | Jul 2012 | A1 |
| 20120199125 | Bowditch et al. | Aug 2012 | A1 |
| 20120203145 | Nilsson | Aug 2012 | A1 |
| 20120203189 | Barta et al. | Aug 2012 | A1 |
| 20120232502 | Lowing | Sep 2012 | A1 |
| 20120238932 | Atteia et al. | Sep 2012 | A1 |
| 20130090615 | Jaeb et al. | Apr 2013 | A1 |
| 20130101804 | Brokken et al. | Apr 2013 | A1 |
| 20130102979 | Coulthard et al. | Apr 2013 | A1 |
| 20130116635 | Fleischmann | May 2013 | A1 |
| 20130138054 | Fleischmann | May 2013 | A1 |
| 20130138060 | Haggstrom et al. | May 2013 | A1 |
| 20130144230 | Wu et al. | Jun 2013 | A1 |
| 20130150814 | Buan | Jun 2013 | A1 |
| 20130165878 | Heagle | Jun 2013 | A1 |
| 20130215638 | Dabov et al. | Aug 2013 | A1 |
| 20130218039 | Sotos et al. | Aug 2013 | A1 |
| 20130274688 | Weston | Oct 2013 | A1 |
| 20130331822 | Patel et al. | Dec 2013 | A1 |
| 20130338613 | Haggstrom et al. | Dec 2013 | A1 |
| 20140005618 | Locke et al. | Jan 2014 | A1 |
| 20140100536 | Angel | Apr 2014 | A1 |
| 20140114268 | Auguste et al. | Apr 2014 | A1 |
| 20140249493 | Hartwell | Sep 2014 | A1 |
| 20140316359 | Collinson et al. | Oct 2014 | A1 |
| 20140330227 | Coulthard et al. | Nov 2014 | A1 |
| 20140343518 | Riesinger | Nov 2014 | A1 |
| 20150057625 | Coulthard | Feb 2015 | A1 |
| 20150065965 | Haggstrom et al. | Mar 2015 | A1 |
| 20150073358 | Jaeb et al. | Mar 2015 | A1 |
| 20150159066 | Hartwell et al. | Jun 2015 | A1 |
| 20150202354 | Wall | Jul 2015 | A1 |
| 20150224238 | Hartwell | Aug 2015 | A1 |
| 20150250931 | Bharti et al. | Sep 2015 | A1 |
| 20150258256 | Jaeb et al. | Sep 2015 | A1 |
| 20160051737 | Joshi et al. | Feb 2016 | A1 |
| 20160058927 | Weston | Mar 2016 | A1 |
| 20160081859 | Hartwell | Mar 2016 | A1 |
| 20160144084 | Collinson et al. | May 2016 | A1 |
| 20160166438 | Rovaniemi | Jun 2016 | A1 |
| 20160206793 | Robinson et al. | Jul 2016 | A1 |
| 20160270967 | Hartwell | Sep 2016 | A1 |
| 20160361473 | Robinson et al. | Dec 2016 | A1 |
| 20170014556 | Haggstrom et al. | Jan 2017 | A1 |
| 20170296714 | Locke et al. | Oct 2017 | A1 |
| 20170304510 | Askem et al. | Oct 2017 | A1 |
| 20170319761 | Locke et al. | Nov 2017 | A1 |
| 20180021178 | Locke et al. | Jan 2018 | A1 |
| 20180028729 | Joshi et al. | Feb 2018 | A1 |
| 20180104393 | Wu et al. | Apr 2018 | A1 |
| 20180311078 | Hartwell | Nov 2018 | A1 |
| 20190142647 | Hartwell | May 2019 | A1 |
| Number | Date | Country |
|---|---|---|
| 201664463 | Dec 2010 | CN |
| 9017289 | Apr 1992 | DE |
| 19844355 | Apr 2000 | DE |
| 0208395 | Jan 1987 | EP |
| 0512543 | Nov 1992 | EP |
| 0541251 | May 1993 | EP |
| 0941726 | Sep 1999 | EP |
| 1411874 | Apr 2004 | EP |
| 1452156 | Sep 2004 | EP |
| 1455701 | Mar 2006 | EP |
| 1448261 | Feb 2007 | EP |
| 1476217 | Mar 2008 | EP |
| 1976477 | Oct 2008 | EP |
| 1507498 | Jul 2009 | EP |
| 1791579 | Jul 2009 | EP |
| 2109472 | Oct 2009 | EP |
| 2161011 | Mar 2010 | EP |
| 1947987 | May 2010 | EP |
| 1358456 | Jul 2010 | EP |
| 2214728 | Aug 2010 | EP |
| 2302127 | Mar 2011 | EP |
| 2340064 | Jul 2011 | EP |
| 2346468 | Jul 2011 | EP |
| 2205190 | Sep 2011 | EP |
| 2366721 | Sep 2011 | EP |
| 2370116 | Oct 2011 | EP |
| 2462908 | Jun 2012 | EP |
| 2529767 | Dec 2012 | EP |
| 2531761 | Dec 2012 | EP |
| 2231088 | Jan 2013 | EP |
| 2015655 | Mar 2013 | EP |
| 2563421 | Mar 2013 | EP |
| 2049055 | Apr 2013 | EP |
| 2596815 | May 2013 | EP |
| 2340062 | Jun 2013 | EP |
| 2603699 | Jun 2013 | EP |
| 1893145 | Jul 2013 | EP |
| 2370142 | Jul 2013 | EP |
| 2279017 | Aug 2013 | EP |
| 2370117 | Aug 2013 | EP |
| 2258443 | Sep 2013 | EP |
| 2263742 | Sep 2013 | EP |
| 1848390 | Dec 2013 | EP |
| 1875081 | Dec 2013 | EP |
| 2271381 | Dec 2013 | EP |
| 2160166 | Jan 2014 | EP |
| 1565219 | Feb 2014 | EP |
| 2305325 | Apr 2014 | EP |
| 2323712 | Apr 2014 | EP |
| 2345437 | Apr 2014 | EP |
| 2051675 | Jun 2014 | EP |
| 1485613 | Jul 2014 | EP |
| 1545644 | Aug 2014 | EP |
| 2416816 | Oct 2014 | EP |
| 2468323 | Oct 2014 | EP |
| 2658493 | Oct 2014 | EP |
| 2268348 | Dec 2014 | EP |
| 2561128 | Jan 2015 | EP |
| 2683285 | Feb 2015 | EP |
| 2470136 | Mar 2015 | EP |
| 2503974 | May 2015 | EP |
| 2249894 | Aug 2015 | EP |
| 2802366 | Aug 2015 | EP |
| 2438302 | Sep 2015 | EP |
| 2346545 | Oct 2015 | EP |
| 2438301 | Oct 2015 | EP |
| 2934402 | Oct 2015 | EP |
| 2802304 | Dec 2015 | EP |
| 2852421 | Jan 2016 | EP |
| 2410962 | Mar 2016 | EP |
| 2640436 | Mar 2016 | EP |
| 2855937 | May 2016 | EP |
| 2433594 | Jun 2016 | EP |
| 2919730 | Jun 2016 | EP |
| 2861869 | Jul 2016 | EP |
| 2293749 | Aug 2016 | EP |
| 3072542 | Sep 2016 | EP |
| 2305327 | Oct 2016 | EP |
| 2467086 | Oct 2016 | EP |
| 2470135 | Oct 2016 | EP |
| 2767305 | Oct 2016 | EP |
| 2462956 | Mar 2017 | EP |
| 1587502 | May 2017 | EP |
| 1587554 | May 2017 | EP |
| 2731563 | May 2017 | EP |
| 2632613 | Aug 2017 | EP |
| 2888478 | Aug 2017 | EP |
| 2937107 | Aug 2017 | EP |
| 3062751 | Aug 2017 | EP |
| 2359784 | Sep 2017 | EP |
| 2367518 | Oct 2017 | EP |
| 2675493 | Oct 2017 | EP |
| 2736548 | Nov 2017 | EP |
| 2593058 | Mar 2018 | EP |
| 2879633 | Aug 2018 | EP |
| 2227203 | Sep 2018 | EP |
| 2696826 | Sep 2018 | EP |
| 3106186 | Sep 2018 | EP |
| 2941280 | Oct 2018 | EP |
| 3120879 | Dec 2018 | EP |
| 2370130 | Mar 2019 | EP |
| 3053609 | Mar 2019 | EP |
| 2285432 | Jun 2019 | EP |
| 2355762 | Sep 2019 | EP |
| 2822613 | Sep 2019 | EP |
| 2863855 | Sep 2019 | EP |
| 2482912 | Oct 2019 | EP |
| 2244756 | Dec 2019 | EP |
| 1163907 | Oct 1958 | FR |
| 2939320 | Jun 2010 | FR |
| 2099306 | Dec 1982 | GB |
| 2435422 | Aug 2007 | GB |
| 2435423 | Aug 2007 | GB |
| 2511523 | Sep 2014 | GB |
| H04354722 | Dec 1992 | JP |
| 2429887 | Sep 2011 | RU |
| 131622 | Aug 2013 | RU |
| WO-9423677 | Oct 1994 | WO |
| WO-9504511 | Feb 1995 | WO |
| WO-9514451 | Jun 1995 | WO |
| WO-9605873 | Feb 1996 | WO |
| WO-9621410 | Jul 1996 | WO |
| WO-9711658 | Apr 1997 | WO |
| WO-9939671 | Aug 1999 | WO |
| WO-0007653 | Feb 2000 | WO |
| WO-0042957 | Jul 2000 | WO |
| WO-0185248 | Nov 2001 | WO |
| WO-0217840 | Mar 2002 | WO |
| WO-0226180 | Apr 2002 | WO |
| WO-0238096 | May 2002 | WO |
| WO-02076379 | Oct 2002 | WO |
| WO-2004073566 | Sep 2004 | WO |
| WO-2005123170 | Dec 2005 | WO |
| WO-2006052839 | May 2006 | WO |
| WO-2007030598 | Mar 2007 | WO |
| WO-2007030601 | Mar 2007 | WO |
| WO-2008049277 | May 2008 | WO |
| WO-2008063281 | May 2008 | WO |
| WO-2008131895 | Nov 2008 | WO |
| WO-2009066105 | May 2009 | WO |
| WO-2009071935 | Jun 2009 | WO |
| WO-2009098696 | Aug 2009 | WO |
| WO-2009120951 | Oct 2009 | WO |
| WO-2009124100 | Oct 2009 | WO |
| WO-2009146441 | Dec 2009 | WO |
| WO-2009158128 | Dec 2009 | WO |
| WO-2010082872 | Jul 2010 | WO |
| WO-2010089448 | Aug 2010 | WO |
| WO-2010139926 | Dec 2010 | WO |
| WO-2010142959 | Dec 2010 | WO |
| WO-2010147533 | Dec 2010 | WO |
| WO-2011023650 | Mar 2011 | WO |
| WO-2011049562 | Apr 2011 | WO |
| WO-2011112724 | Sep 2011 | WO |
| WO-2011115908 | Sep 2011 | WO |
| WO-2011128651 | Oct 2011 | WO |
| WO-2011130570 | Oct 2011 | WO |
| WO-2011135285 | Nov 2011 | WO |
| WO-2011135286 | Nov 2011 | WO |
| WO-2011135287 | Nov 2011 | WO |
| WO-2011144888 | Nov 2011 | WO |
| WO-2011146532 | Nov 2011 | WO |
| WO-2012009370 | Jan 2012 | WO |
| WO-2012069793 | May 2012 | WO |
| WO-2012069794 | May 2012 | WO |
| WO-2012074512 | Jun 2012 | WO |
| WO-2012131237 | Oct 2012 | WO |
| WO-2012140378 | Oct 2012 | WO |
| WO-2012143665 | Oct 2012 | WO |
| WO-2012146656 | Nov 2012 | WO |
| WO-2012150235 | Nov 2012 | WO |
| WO-2013010907 | Jan 2013 | WO |
| WO-2013076450 | May 2013 | WO |
| WO-2013083800 | Jun 2013 | WO |
| WO-2013118447 | Aug 2013 | WO |
| WO-2013136181 | Sep 2013 | WO |
| WO-2013149078 | Oct 2013 | WO |
| WO-2013175306 | Nov 2013 | WO |
| WO-2014016759 | Jan 2014 | WO |
| WO-2014020440 | Feb 2014 | WO |
| WO-2014020443 | Feb 2014 | WO |
| WO-2014099709 | Jun 2014 | WO |
| WO-2014108476 | Jul 2014 | WO |
| WO-2014113253 | Jul 2014 | WO |
| WO-2016107775 | Jul 2016 | WO |
| WO-2016174048 | Nov 2016 | WO |
| Entry |
|---|
| Annex to the Communication, the Opposition of European Patent No. 2825220, mailed on May 10, 2019, 17 pages. |
| Closure of the appeal proceedings for European Patent No. 2825220 mailed on Oct. 14, 2020, 2 pages. |
| Communication of the registration of a transfer or change of name and or address for European Patent No. EP2825220, dated Jan. 27, 2021, 2 pages. |
| Grounds for the Decision and Annex to the Communication, Opposition of European Patent No. 2825220, mailed on Feb. 6, 2020, 184 pages. |
| Information about the Result of Oral Proceedings for the Opposition of European Patent No. 2825220, mailed on Dec. 5, 2019, 4 pages. |
| International Preliminary Report on Patentability for Application No. PCT/IB2013/000847, dated Sep. 25, 2014, 14 pages. |
| International Search Report and Written Opinion for Application No. PCT/IB2013/000847, dated Aug. 30, 2013, 20 pages. |
| Kendall ULTEC Hydrocolloid Dressing (4×4″), Product Ordering Page, web page downloaded on Jul. 13, 2014, 1 page. |
| Maintenance of the patent with the documents specified in the final decision for European patent No. 2825220 dated Oct. 13, 2020, 1 page. |
| Notice of Appeal against the Interlocutory Decision of the Opposition Division against European Patent No. 2825220, mailed on Apr. 6, 2020, 4 pages. |
| Notice of Opposition—Statement of Facts and Evidence for European Patent No. 2825220, mailed on Sep. 20, 2018, 15 pages. |
| Proprietor's Written Submission in Preparation for the Oral Proceedings for the Opposition of European Patent No. 2825220, mailed on Oct. 4, 2019, 13 pages. |
| Protz K., “Modern Wound Dressings Support the Healing Process,” Wound care: Indications and Application, Geriatrie Journal, Apr. 2005, pp. 3333-3339 (17 pages with English translation). |
| Reply of the Patent Proprietor to the Notice of Opposition of the European Patent No. 2825220, mailed Feb. 13, 2019, 28 pages. |
| Statement of Ground of Appeal filed by proprietor for European patent No. 2825220 mailed on Jun. 5, 2020, 16 pages. |
| Termination of the opposition proceedings with maintenance of European Patent No. EP2825220, dated Jan. 29, 2021, 1 page. |
| Withdrawal of an appeal from the opponent for European patent No. 2825220 mailed on Oct. 7, 2020, 3 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20210361854 A1 | Nov 2021 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61609905 | Mar 2012 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16047786 | Jul 2018 | US |
| Child | 17397860 | US | |
| Parent | 14385136 | US | |
| Child | 16047786 | US |
